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ABSTRACT 
 
Atherosclerosis is a chronic disease of large and medium sized arteries, characterized by 
retention of lipoproteins and accumulation of cholesterol in the arterial wall and 
subsequent narrowing of the arterial lumen. Atherosclerosis is the main cause of death in 
Western countries. The use of hormone replacement therapy (HRT) to prevent 
atherosclerosis has been an area of controversy in recent years. However, despite a 
multitude of earlier studies, there were no previous randomized clinical trials on whether 
estrogen treatment and estrogen receptor gene variation influence the progression of 
atherosclerosis in women. Moderate ethanol consumption has been shown to affect the 
serum lipid profile favorably, and there is a J-shaped association between alcohol 
consumption and the incidence of coronary heart disease. Nevertheless, associations 
between the lipid profile and the biomarkers of alcohol consumption carbohydrate-
deficient transferrin (CDT) and gamma-glutamyl transferase (GGT) were unresolved.  
The aims of this study were to investigate the possible effects of postmenopausal 
HRT on the oxidation of low density lipoprotein (LDL) particles and progression of 
cardiovascular diseases and to look for associations between the genotype of estrogen 
receptor and progression of atherosclerosis. The effects of alcohol consumption on the 
lipid profile were studied in relation to laboratory biomarkers of alcohol use. 
Postmenopausal HRT by estradiol valerate alone, combined estradiol valerate–
levonorgestrel, and combined estradiol valerate–medroxyprogesterone acetate was found 
to be associated with less severe atherosclerotic lesions and diminished LDL oxidation. 
Genetic variation in the estrogen gene may modulate the effect of postmenopausal 
estrogen therapy on progression of atherosclerosis. Alcohol consumption, associated with 
high serum CDT concentration, was associated with a favorable anti-atherogenic lipid 
profile, whereas alcohol consumption associated with liver induction and elevated serum 
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GGT activity may favor pro-atherogenic effects on lipid profile. Thus, the biomarkers of 
alcohol consumption, CDT and GGT seem to detect different populations of subjects in 
regard to cardiovascular lipid risk factors. 
 
Keywords: atherosclerosis, cholesterol, carbohydrate-deficient transferrin, estrogen 
receptor genotype, gamma-glutamyl transferase, hormone replacement therapy, alcohol, 
serum lipids. 
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TIIVISTELMÄ 
 
Valtimonkovettumatauti eli ateroskleroosi on suurten ja keskikokoisten valtimoiden 
krooninen tauti, jolle on ominaista kolesterolin kertyminen valtimon seinämään ja 
valtimon ontelon kaventuminen. Ateroskleroosi on yleisin kuolinsyy länsimaissa. 
Hormonikorvaushoidon käyttäminen ateroskleroosin ehkäisyyn on ollut kiistanalainen 
kysymys viime vuosina. Vaikka tutkimuksia on ollut paljon, estrogeenihoidon tai 
estrogeenireseptorin geneettisen variaation vaikutusta ateroskleroosin etenemiseen ei ole 
aikaisemmin tutkittu satunnaistetussa kliinisessä tutkimuksessa. Kohtuullisen alkoholin 
kulutuksen on todettu vaikuttavan suotuisasti seerumin lipideihin. Alkoholin ja 
sydäntaudin päätetapahtumien välinen yhteys näyttää olevan J-käyrän muotoinen. 
Seerumista mitattavien alkoholinkulutusta heijastavien biomarkkereiden 
hiilihydraattiköyhän transferriinin (CDT) ja gamma-glutamyylitransferaasin (GGT) yhteys 
seerumin lipidiprofiiliin tunnetaan huonommin. 
Tutkimuksessa selvitettiin vaihdevuosien jälkeisen hormonikorvaushoidon 
mahdollisia vaikutuksia low density lipoproteiinien (LDL) hapettumiseen ja sydän- ja 
verisuonitautien kehittymiseen sekä selvitettiin estrogeenireseptorin genotyypin yhteyttä 
ateroskleroosin etenemiseen. Alkoholinkäytön vaikutusta seerumin lipideihin tutkittiin 
suhteessa sen kulutusta heijastaviin seerumin biomarkkereihin. 
Vaihdevuosien jälkeinen hormonikorvaushoito estradiolivaleraatilla, yhdistetyllä 
estradiolivaleraatti-levonorgestreelillä, ja yhdistetyllä estradiolivaleraatti– 
medroksiprogesteroniasetaatilla oli yhteydessä lievempiasteiseen ateroskleroosiin ja 
vähentyneeseen LDL:n hapettumiseen. Estrogeenireseptorin geenivaihtelu saattaa 
vaikuttaa valtimoiden kovettumistaudin kehittymiseen hormonikorvaushoidon aikana. 
Alkoholinkäyttö, johon liittyy kohonnut seerumin CDT-pitoisuus, oli yhteydessä 
suotuisaan lipidiprofiiliin, kun taas alkoholinkäyttö johon liittyy maksan induktio ja 
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kohonnut seerumin GGT-aktiivisuus, näyttää olevan yhteydessä epäsuotuisaan 
lipidiprofiiliin. Näin ollen alkoholin kulutuksen biomarkkerit CDT ja GGT näyttävät 
tunnistavan väestöryhmät, joilla on erilainen sydän- ja verisuonitautien riski lipidien 
osalta. 
 
Avainsanat: ateroskleroosi, hormonikorvaushoito, estrogeenireseptorin genotyyppi, 
alkoholi, kolesteroli, seerumin lipidit. 
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ABBREVIATIONS 
 
ANOVA analysis of  variance 
AS  atherosclerotic severity sum 
BHT  butylated hydroxytoluene 
BMI  body mass index 
CCA  common carotid artery 
CAD  coronary artery disease 
CDT  carbohydrate-deficient transferrin 
ESR  estrogen receptor 
ESR1  estrogen receptor alfa 
ESR2  estrogen receptor beta 
EV  estradiol valeriate 
GGT  gamma-glutamyl transferase 
CVD  cardiovascular disease 
HDL  high density lipoprotein 
HERS  Heart Estrogen/progestin Replacement Study 
HRT  hormone replacement therapy 
HSA  human serum albumin 
IDL  intermediate density lipoprotein 
LDL  low density lipoprotein 
M  progestin, medroxyprogesterone 
MI  myocardial infarction 
NAP  number of atherosclerotic plaques 
OD  optical density 
oxLDL  oxidized low density lipoprotein 
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P  progestin, levonorgestrel 
PBS  phosphate buffered saline  
RCT  reverse cholesterol transport 
SMC  smooth muscle cell 
VLDL  very low density lipoprotein 
WHI  Women’s Health Initiative 
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1. INTRODUCTION 
 
Atherosclerosis is a chronic disease of large and medium sized arteries. It has a 
multifactorial origin and is characterized by accumulation of intracellular and extracellular 
cholesterol in the arterial wall with subsequent narrowing of the arterial lumen (Fuster et 
al. 1992a, Fuster et al. 1992b). Inflammation plays an important role in the progression of 
atherosclerosis (Ross 1999). There is a chronic inflammatory process in the 
atherosclerotic plaque, which has a major role in plaque growth and rupture. Plaques that 
are prone to rupture have often numerous inflammatory cells and a thin fibrous cap (Stoll 
and Bendszus 2006). Physiological disruption of atheromatous lesions often underlies 
acute coronary syndromes such as myocardial infarction (MI), angina, or sudden death due 
to coronary artery occlusion (Falk 1983).  
It is well known that increase in serum LDL is a risk factor for atherosclerosis. 
Oxidative modification of LDL makes it more atherogenic than its native form. Oxidized 
LDL (oxLDL) is taken up by macrophages via the scavenger receptors leading to foam 
cell formation and fatty streak development (Steinberg et al. 1989). OxLDL is 
immunogenic and induces the formation of autoantibodies, which have been detected in 
human and animal plasma and atherosclerotic plaques (Ylä-Herttuala et al. 1994). OxLDL 
autoantibodies have been suggested to predict rapid progression of atherosclerosis in 
humans (Salonen JT et al. 1992, Puurunen M et al. 1994, Wu et al. 1997). On the other 
hand, oxLDL has also been reported to have no effect on atherosclerosis (van de Vijver et 
al. 1996), or even a beneficial effect (Fukumoto et al. 2000). Despite the contradictory 
results concerning the involvement of oxLDL autoantibodies in the pathogenesis of 
atherosclerosis, autoantibodies may be useful in specifically evaluating the presence of 
oxLDL in the arterial wall (Tsimikas et al. 2001). 
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HRT is often given for women as a short-term relief from menopausal symptoms. 
The use of HRT to prevent heart disease has been an area of controversy in recent years 
after negative results in randomized trials (Brinton et al. 2008). This thesis studied the 
effect of HRT on the progression of atherosclerosis and the relation of this therapy to the 
level of oxLDL autoantibodies – a risk factor for atherosclerosis. We then wanted to find 
out whether there was a genetic subgroup of women who would benefit more from 
estrogens than others. In fact, an important hypothesis of this thesis was that some women 
would receive more atheroprotective benefit than others from HRT depending on their 
estrogen receptor alfa (ESR1) genotype.  
The per capita alcohol consumption in Finland has steadily increased. During the 
last two decades, the number of alcohol related deaths has doubled, and in 2008 alcohol 
caused more deaths of men aged 15 to 64 years than coronary artery disease (CAD) 
(Statistics Finland 2009). Moderate alcohol consumption is not considered a risk factor for 
atherosclerosis, but excessive alcohol consumption increases the risk for cardiovascular 
complications. Two cross-sectional studies were carried out to assess the relation between 
biomarkers of alcohol intake CDT and GGT and serum lipids. 
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2. REVIEW OF THE LITERATURE 
 
2.1. The structure of arteries 
 
The artery wall consists of three layers, the intima, media and adventitia (Stary et al. 
1992). The intima includes a monolayer of endothelial cells or endothelium and a 
subendothelial space containing extracellular matrix and smooth muscle cells (SMC). 
Also macrophages, T-lymphocytes and mast cells may be present. The thickness of the 
intima varies greatly depending on the size and type of artery. Between the intima and 
media is the fenestrated internal elastic lamina (Stary et al. 1992). The media consists 
mainly of layers of SMCs that maintain arterial tone. The external elastic lamina separates 
the media from the adventitia, the outermost layer, which is connective tissue and contains 
fibroblasts, vasa vasorum and nerves (Geer and Haust 1972, Stary et al. 1992, Kovanen et 
al. 1995). 
The thickness of the intima increases through the activation of a subgroup of 
native intimal SMC. Intimal thickening begins already during fetal life (Stary 2000). 
Diffuse and eccentric thickenings are produced. Diffuse intimal thickenings involving the 
whole circumference of the artery are found in all anatomic locations of medium and large 
arteries, but eccentric thickenings that cover less than half of the circumference are 
localized to arterial bifurcations (Geer and Haust 1972, Stary et al. 1992, Stary 1987). 
Eccentric thickenings may be adaptations to “disturbed” shear stress conditions at arterial 
bifurcations (Davies 1995, Gimbrone et al. 2000), and it is thought that atherosclerosis 
progresses more rapidly in these regions than elsewhere (Stary et al. 1992).  
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2.2. Atherosclerosis 
 
2.2.1. Risk factors of atherosclerosis 
 
The classical risk factors for formation of atherosclerotic lesions include environmental 
factors, such as smoking, lack of exercise, high fat diet and infectious agents. In addition, 
also factors with a significant genetic component are strongly associated with 
atherosclerosis. These include high serum cholesterol, especially LDL cholesterol, low 
levels of high density lipoprotein (HDL), male gender, diabetes mellitus and arterial 
hypertension (for review, see Glass and Witztum, 2001).  
 
2.2.2. Metabolism of cholesterol in lipoproteins 
 
Serum cholesterol transport occurs through different lipoprotein particles that are 
composed of lipids and apolipoproteins (Witztum and Steinberg, 1995). Dietary 
cholesterol is absorbed in the intestine and packed into triglyceride-rich chylomicrons that 
contain apolipoproteins B-48 and E. In tissue capillaries the enzyme lipoprotein lipase 
hydrolyzes a large part of chylomicrons’ triacylglycerol to glycerol and free fatty acids. 
The remaining smaller chylomicron particle is taken up by the liver (for review, see Glass 
and Witztum, 2001). 
The liver synthesises triglyceride-rich very low density lipoprotein (VLDL) 
particles containing apolipoprotein B-100 and apolipoproteins E and C. Triacylglycerol is 
removed from VLDL in peripheral tissues by lipoprotein lipase and VLDL remnants are 
converted to intermediate density lipoprotein (IDL), which are either taken up by the liver 
or converted to LDL by hepatic lipase. Two thirds of plasma cholesterol is carried by LDL 
with apolipoprotein apoB-100. LDL is subsequently taken up by peripheral tissues and the 
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liver by the LDL receptors that recognize apoB-100. Free cholesterol is released into the 
cell after lysosomal enzymes hydrolyze LDL. Increased LDL cholesterol levels have been 
shown to be associated with increased risk of atherosclerosis (for review, see Glass and 
Witztum, 2001). 
One third of the plasma cholesterol is carried by HDL, and its main apoprotein is 
apoA-I (Oram et al. 2006). HDL has a major role in reverse cholesterol transport (RCT), 
since it accepts free cholesterol from peripheral tissues, esterifies it by the enzyme 
lecithin:cholesterol acyl transferase, and is taken up by the liver by hepatic scavenger 
receptor BI. It also exchanges cholesterol with other lipoproteins through cholesteryl ester 
transfer protein (Acton et al. 1996). 
 
2.2.3. Oxidation of LDL particles 
 
OxLDL has a significant role in the progression of atherosclerosis (Steinbrecher et al. 
1989, Parthasarathy et al. 1990, Parthasarathy et al. 1992). OxLDL accumulates in 
macrophages, accelerates the development of foam cells and stimulates the adhesion of 
monocytes to endothelium (Jialal and Devaraj 1996, Witztum and Steinberg 1991, 
Witztum 1991). The small, dense LDL particles are more susceptible to oxidation, which 
mainly takes place in the arterial wall (Lehtimäki et al. 1999, Krauss 1995, Galeano et al. 
1998). The antibody titers of oxLDL have been shown to correlate with the severity of 
atherosclerosis and it has been thought to predict MI (Salonen et al. 1992, Wu et al. 1997) 
and restenosis (Eber et al. 1994).  
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2.2.4. Atherosclerotic lesions 
 
Atherosclerotic lesions are formed when the influx of atherogenic lipoproteins is 
excessive at susceptible intimal thickenings of large arteries (McGill and McMahan 1998, 
Williams and Tabas 1995, Williams and Tabas 1998, Kadar and Glasz 2001, Witztum and 
Steinberg 1991). Trapping of LDL by the extracellular matrix proteoglycans lengthens its 
residence time in the intima and predisposes it to modifications, such as metal catalyzed 
oxidation, nonenzymatic glycosylation or lipolysis and proteolysis by enzymes derived 
from intimal cells (Ross 1993). Modification of LDL is often needed for its enhanced 
uptake by monocyte-derived macrophages (Witztum and Steinberg 1991). OxLDL as well 
as modified LDL generally are taken up by macrophages via scavenger receptors, leading 
to foam cell formation. This is prerequisite for atherosclerotic plaque formation. The 
Committee on Vascular Lesions of the Council of Atherosclerosis, American Heart 
Association (Stary et al. 1992, Stary et al. 1994, Stary et al. 1995) has established a 
specific classification of atherosclerotic lesions, based on histology (Figures 1 and 2). This 
classification divides the lesions into early (I-III) and advanced (IV-VI) types.  
Classification of early lesions include types I, II and III.  Type I lesions only 
contain foam cells without other significant histological changes (Stary et al. 1994). At the 
next stage, type II lesions form on the inner surfaces of arteries. They are relatively flat, 
yellow-colored streaks or patches. Type II lesions are called fatty streaks and consist 
primarily of macrophage foam cells, but SMC-derived foam cells may also be present. 
The lipid in these cells is primarily cholesterol and its esters. Type III lesions also contain 
extracellular lipid droplets derived from apoptotic macrophage foam cells in small pools 
below the macrophage layer. Types I and II and possibly also type III lesions are relatively 
innocuous and can either regress, or progress depending on favorable or unfavorable 
changes in risk factors (Stary 2000). 
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Figure 1. Classification of atherosclerotic lesions (Stary et al. 1995). 
 
Advanced atherosclerotic lesions are classified into type IV – VI. Type IV lesions, 
also known as the atheromas, evolve from the type II lesions by accumulation and fusion of 
extracellular lipid pools in the intima, called the lipid core. On top of the lipid core is a thin 
layer of proteoglycan-rich intercellular matrix containing macrophages, SMCs, mast cells 
and lymphocytes (Stary et al. 1995, Kovanen et al. 1995, Kaartinen et al. 1998). What 
makes these lesions dangerous is that they are asymptomatic, not visible by angiography 
and the thin cap is prone to rupture (MacIsaac et al. 1993, Schroeder and Falk 1995, Davies 
1997, Felton et al. 1997). Type V lesions or fibroatheromas, have a prominent fibrous cap 
of connective tissue between the lipid core and endothelium, and are thus less prone to 
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rupture. They cause various narrowing of arteries and are often symptomatic due to reduced 
blood flow of the affected tissue or organ. Fibroatheromas often progress to type VI 
complicated lesions that show hematoma, hemorrhage or thrombosis. These lesions are 
unstable and may cause acute complications of atherosclerosis, such as MI and stroke.  On 
the other hand, if the thrombogenic stimulus is relatively limited, it may only lead to local 
plaque growth. (Stary et al. 1995, Fuster et al. 1992a, Fuster et al. 1992b, Stary 2000). 
 
Figure 2. Cross-sections of atherosclerotic lesion types I-VI (Stary et al. 1995). 
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2.3. Estrogens  
 
2.3.1. Estrogens and the cardiovascular system 
 
The incidence of CHD in premenopausal women is about one-half of that in men of 
similar age (Ross et al. 1981, Nabulsi et al. 1993, Chae et al. 1997). Since the incidence of 
CHD rises soon after menopause, estrogens may play a fundamental role as 
cardioprotective agents (Barret-Connor and Bush 1991, Mendelsohn and Karas 1994, van 
der Schouw et al. 1996, Hu et al. 1999). Estrogens suppress arterial SMC proliferation and 
migration (Dai-Do et al. 1996), and they increase the synthesis of collagen and elastin in 
the arterial intima (Fischer and Swain 1985). Estrogens reduce the accumulation of 
cholesterol in the arterial wall (Haarbo et al. 1991, Wagner et al. 1991), and protect LDL 
from oxidation in vitro (Huber et al. 1990).  
The proposed cardioprotective effects of estrogen are thought to be mediated both 
by alterations of lipoprotein/lipid profiles and by direct effects on the vessel wall, 
estrogens i.e. display endothelotherapeutic functions (Mendelsohn 2002). Estrogens are 
known to increase HDL cholesterol and reduce both total and LDL cholesterol (Walsh et 
al. 1991, Stevenson et al. 1993, Davis et al. 1994, Tremollieres et al. 1999, Tikkanen et al. 
1979), thus generating a favourable lipid profile.  On the other hand, it has been argued 
that the age-related changes in lipids might be due to differences in also other sex 
hormones, such as testosterone (Rossouw 2002, Smiley and Khalil 2009). Summing up so 
far, these effects in serum lipids have been estimated to account for only approximately 
one third of the atheroprotective effects associated to estrogen (Bush et al. 1987, 
Mendelsohn and Karas 1994). 
Direct vascular effects of estrogen on the vessel wall are in part mediated by 
estrogen–induced changes in gene expression (Vargas et al. 1993, Weiner et al. 1994, 
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Farhat et al. 1996, Chen et al. 1999). Estrogen has been shown to alter the expression of a 
number of genes in vascular wall cells, including endothelial nitric oxide synthase, cyclo-
oxygenase, prostacyclin synthase, inducible nitric oxide synthase, endothelin-1, collagens, 
matrix metalloproteinases, vascular cell adhesion molecule, vascular endothelial growth 
factor, elastin, c-fos and progesterone receptor (reviewed by Mendelsohn and Karas 
1999). Furthermore, estrogens have been proposed to act also by rapid 
“nontranscriptional” signaling actions independent of the synthesis of mRNA. At this 
level, estrogen triggers rapid vasodilatation, exerts anti-inflammatory effects, stimulates 
endothelial growth, migration and repair, and protects the vessels from atherosclerotic 
degeneration (Simoncini et al. 2006). Some proposed nongenomic and genomic vascular 
effects of estrogens are shown in Figure 3. 
 
Figure 3. Estrogenic effects on atherosclerosis (Mendelsohn and Karas 1999).  
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2.3.2. Hormone replacement therapy (HRT) and health  
 
Generally, HRT is used for two primary reasons. Firstly, HRT is used in premenopausal 
women with certain health conditions, for example in premature ovarian failure (De Vos 
et al. 2010). HRT helps in maintaining bone health (Pinkerton and Stovall 2010) and 
reducing the risk of heart disease (Jeanes et al. 2007). Secondly, menopausal and post-
menopausal women use HRT to reduce some of the menopausal symptoms, such as hot 
flashes, night sweats, vaginal dryness and sleep disturbances. It is considered that HRT 
taken by women with certain health conditions is different than that taken by post-
menopausal women. The risks associated with post-menopausal HRT do not apply to pre-
menopausal women taking HRT (Writing Group for the Women's Health Initiative 
Investigators 2002).  
Previous studies have suggested that HRT is beneficial with respect to health in 
postmenopausal women (Ross et al. 1981, Nabulsi et al. 1993, Chae et al. 1997, Stampfer 
and Colditz 1991, Stampfer et al. 1991, Punnonen et al. 1995, Grady et al. 1992, 
Grodstein et al. 1997, Mijatovic et al. 1997). However, this concensus is far from clear at 
present. One of the largest studies of HRT, the Women’s Health Initiative (WHI) 
Hormone Replacement study was designed to explore the usefulness of HRT in 
preventing disease – particularly heart disease (Writing Group for the Women's Health 
Initiative Investigators 2002). It was halted in 2002 because women taking the hormones 
after menopause had a greater risk of breast cancer, heart attack, stroke and blood clots 
than those who did not take the drugs (Writing Group for the Women's Health Initiative 
Investigators 2002). However, there were also benefits of estrogen plus progestin 
compared to those who did not take the hormones, including fewer cases of hip fractures 
and colon cancer.  
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Recently Stevenson et al. evaluated the WHI study. They state that the initially 
published results suggested overall harm from HRT, leading to a dramatic worldwide 
decrease in its use, and concerns from clinicians and regulatory authorities. Subsequent 
publications with more detailed analyses appear to have countermanded these initial 
concerns. Analyses of the studies have not been adherent to those specified in the original 
published protocol. Initially reported as showing a significant increase in adverse health 
events with HRT, in a subsequent analysis of the full data the increase was no longer 
significant. The writers suggest that the raw data should be made available for 
independent assessment to obtain valid conclusions which may again change clinical 
practice (Stevenson et al. 2009). 
 
2.3.3. HRT and the development of atherosclerosis 
 
The use of HRT to prevent cardiovascular disease (CVD) has been an area of controversy 
in recent years. Many animal studies show a clear atheroprotective benefit of estrogen. 
Estrogen treatment of cholesterol-fed primates and rabbits inhibits the development of 
atherosclerosis from a 35 % up to an 80 % reduction in lesion size measured in aortic and 
coronary arteries (Hodgin and Maeda 2002). Animal studies have suggested that estrogen 
targets atherogenic processes at early stages of lesion development (Hodgin et al. 2001, 
Hodgin and Maeda 2002). Likewise, other animal studies have also shown that inhibitory 
effects of estrogen may be lost once atherosclerotic lesions are established (Williams et al. 
1995, Hanke et al. 1999). This proposed mechanism, based on animal studies, might be an 
explanation to why trials of HRT in women have shown no cardioprotection if started late 
in menopause (Herrington et al 2002, Rossouw et al. 2002).  
Most epidemiological studies suggest useful effects of estrogens on the risk of 
CVD in postmenopausal women (Ross et al. 1981, Stampfer and Colditz 1991, Stampfer 
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et al. 1991). Although numerous findings from non-randomised experiments show that 
postmenopausal estrogen therapy slows the development of atherosclerotic disease 
(Mendelsohn and Karas 1999, Farhat et al. 1996), estrogens have not been shown to slow 
atherosclerotic progression in women in randomised clinical trials (Hulley et al. 1998, 
Herrington 1999). It seems that the discrepancies in results between observational and 
randomized studies from cardioprotective point of view might be explained by differences 
in selection of participating women, hormone preparations and time elapsed since 
menopause. Indeed, in a re-analysis of postmenopausal women in the Nurses' Health 
Study, women beginning HRT near menopause had a significantly reduced risk of CHD, 
again confirming CHD benefit with HRT in younger women (Grodstein et al. 2006). 
 
2.3.4. Effects of HRT on lipids    
 
Before menopause, serum LDL cholesterol levels are lower and HDL cholesterol levels 
higher in women compared with men of the same age. After menopause, the levels of LDL 
cholesterol rise and HDL cholesterol levels decline (Stevenson et al. 1993, Campos et al. 
1988, Brown et al. 1993). Postmenopausal estrogen therapy has favorable effects on 
serum lipoprotein concentrations (Mendelsohn and Karas 1999, Farhat et al. 1996). Orally 
administered estrogens favorably reduce serum levels of LDL cholesterol and increase 
levels of HDL cholesterol, each by about 15%, but unfavorably increase levels of 
triglycerides by 20% to 25% in postmenopausal women (Tikkanen et al. 1978, Granfone 
et al. 1992, Lobo 1991, Walsh et al. 1991, The Writing Group for the PEPI Trial 1995, 
Koh and Sakuma 2004). Postmenopausal HRT ordinarily involves estrogen combined 
with progestin. In Finland, the progestins that are currently combined with estrogen for 
sequential HRT are norethisterone, medroxyprogesterone and dydrogesterone. It is known 
that some progestins have unfavorable effects on lipid metabolism, while some do not 
 26 
(Barnes et al. 1985, Hirvonen et al. 1981, Sonnendecker et al. 1989). Androgenic 
progestogens of the 19-nortestosterone series (not used in Finland) reverse the beneficial 
effect of postmenopausal estrogen treatment on HDL cholesterol, whereas the 
hydroxyprogesterone derivative medroxyprogesterone has no such effect (Hirvonen et al. 
1981). Recently it has also been shown that RCT is enhanced by HDL-associated estradiol 
esters (Badeau et al. 2009).  
 
2.3.5. HRT and oxidized LDL 
 
Modification of LDL in the intima is thought to play an important role in the progression 
of atherosclerosis (Parthasarathy et al. 1992). Some form of modification of LDL is a 
prerequisite for rapid accumulation of LDL in macrophages and for the formation of foam 
cells. LDL isolated from atherosclerotic lesions, but not from normal arteries, resembles 
oxidized LDL in its physical, chemical, and immunological properties (Ylä-Herttuala et al. 
1988, Ylä-Herttuala et al. 1994). Epitopes displaying characteristics of oxidized LDL can 
be found in atherosclerotic lesions by immunocytochemical techniques (Palinski et al. 
1989, Ylä-Herttuala et al. 1989) and furthermore atherosclerotic lesions contain 
immunoglobulins that recognize oxidized LDL (Ylä-Herttuala et al. 1994, Palinski et al. 
1989). In addition, antioxidant therapy reduces atherogenesis in animal models (Carew et 
al. 1987, Kita et al. 1987). Antibodies against malondialdehyde- or copper modified LDL, 
detected by radioimmunoassay, have been reported to be predictive of the progression of 
carotid atherosclerosis (Salonen et al. 1992), CAD (Lehtimäki et al. 1999) and MI 
(Puurunen et al. 1994). Furthermore, antibodies against copper-oxidized LDL are 
associated with impaired endothelial function and early atherosclerotic changes (Heitzer et 
al. 1996, Raitakari et al. 1997, Lehtimäki et al. 1999). However, HRT has not been shown 
to influence oxLDL antibody titers (Heikkinen et al. 1998). 
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2.4. Estrogen receptors (ESR) 
 
2.4.1. Types of ESR 
 
Currently, two nuclear estrogen receptors, estrogen receptor alpha (ERα or ESR1) (Green 
et al. 1986) and estrogen receptor beta (ERβ or ESR2) (Mosselman et al. 1996) are known 
in humans. In addition, an estrogen membrane receptor coupled to a G protein (GPR30, 
G-protein-coupled receptor 30) (Thomas et al. 2005, Revankar et al. 2005) has been 
identified in human arteries and veins (Haas et al. 2007). ESR1 is expressed in vascular 
endothelial cells (Kim-Schulze et al. 1996, Venkov et al. 1996) and SMCs (Karas et al. 
1994). ESR1 activates specific target genes in vascular smooth muscle (Karas et al. 1994), 
inhibits SMC migration (Kolodgie et al. 1996, Bhalla et al. 1997) and accelerates 
endothelial cell growth in vitro (Morales et al. 1995) and vivo (Krasinski et al. 1997, 
Venkov et al. 1996). ESR numbers are higher in females because estrogen production 
induces their expression (Mendelsohn and Karas 1999). However, atherosclerotic 
coronary arteries of premenopausal women have fewer ESR1 compared to normal arteries 
(Losordo et al. 1994).  
 
2.4.2. Genotypes of the ESR1 and coronary artery disease 
 
Allelic variants of the ESR1 gene may have an effect on the amount and function of the 
expressed receptor. Therefore, it is possible that the effects of estrogens on vascular cells, 
mediated by ESR1, differ due to the ESR1 variant forms that have different transcriptional 
effects than the ‘wild-type’ receptor (Matsubara et al. 1997, Maruyama et al. 2000). The 
most investigated ESR1 polymorphic sites, associated with risk of CVD, are three tightly 
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linked polymorphisms, namely c.454-397 T/C (PvuII, rs2234693),  c.454-351 A/G in 
intron 1 (XbaI, rs 9340799), and the (TA)n VNTR (variable number of tandem repeat) in 
the promoter region.    
The c.454-397T/C genotype (PvuII, rs2234693) consists of a two-allele 
polymorphism for PvuII restriction enzyme, leading to genotypes P/P, P/p, and p/p (Yaich 
1992). The capital letters are used to signify the absence of restriction sites (mutated) and 
small letters the presence of restriction sites (wild type). These genotypes are referred to 
by -397(PP), (Pp), and (pp), or (CC), (CT), and (TT), respectively. The PvuII 
polymorphism is caused by a T-to-C transition in intron 1, and located approximately 0.4 
kb upstream of exon 2 (Yaich 1992). This polymorphism is intronic in nature, and its 
mechanism of action is not clear.  It has been speculated that the PvuII polymorphism may 
alter transcription factor binding and affect expression level of the ESR1 protein 
(Shearman 2006).  
It has been reported that men with the C-allele of the c.454-397T/C polymorphism 
had more severe CAD compared to men with the TT genotype (Lehtimäki et al. 2002). 
The Framingham study and another large follow-up study also reported an increased risk 
of MI among men with the CC genotype (Shearman et al. 2003, Shearman et al. 2006). On 
the other hand, two large case-control studies from Denmark (Kjaergaard et al. 2007) and 
Germany (Koch et al. 2005) failed to detect an increased risk of MI with the −397T/C  
genotype. A weakness of the German study was that the control subjects were not healthy 
since all had some indication for coronary angiography. Likewise, in sub-analysis of 
younger men in the Danish case-cohort study, an increased risk of MI in the CC genotype 
group was found. Even more recently, it has been shown at the population level, using a 
case-cohort design, that in men, the minor CC genotype of the ESR1 −397T/C 
polymorphism contributed to a higher risk of CHD, compared to those with the T-allele 
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(Kunnas et al. 2010). In conclusion, current data supports the view that homozygosity for 
allele −397C of the ESR1 gene (CC) contributes to the risk of CHD. 
 
2.5. Alcohol 
 
2.5.1. Gamma-glutamyl transferase (GGT) and carbohydrate-deficient transferrin 
(CDT) as markers of ethanol consumption 
 
Serum CDT and GGT (also known as gamma-glutamyl transpeptidase) are generally 
considered to be useful laboratory markers for high alcohol consumption (Mihas and 
Tavassoli 1992, Stibler 1991, Sillanaukee 1996). CDT is currently considered to be the 
most useful marker of alcohol misuse (Hannuksela et al. 2007). Transferrin is a 
monomeric, iron-binding glycoprotein, which is synthesized in the liver. Chronic alcohol 
consumption leads to deficiencies in the carbohydrate content of the protein by a yet 
unknown mechanism, leading to increases in serum concentrations of CDT (De Jong et al. 
1990). The exact mechanisms are not fully understood, but ethanol is thought to affect 
both protein transport and enzyme activities (Hannuksela et al. 2007). The use of an array 
of methods for measurement of CDT  either in absolute or relative amounts, and possibly 
covering different transferrin glycoforms, has complicated the comparability of results 
(Helander et al. 2010). 
GGT is known to reflect liver function and its activity in serum may be increased 
by alcohol and other liver microsomal inducing agents, in most hepatobiliary disorders, 
obesity, diabetes mellitus and hypertriglyceridemia (Sabesin 1981). Elevation of GGT in 
serum probably reflects its enhanced hepatic synthesis rate, increased transport to the liver 
plasma membranes, as well as liver plasma membrane injury (Teschke and Koch 1986, 
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Nakajima et al. 1994). Release of GGT may be induced by toxic substances (including 
alcohol), as a result of ischemia, or by damage to hepatocytes due to infection 
(Hannuksela et al. 2007).  
Both CDT and GGT are markers of alcohol consumption, but their serum values 
do not correlate with each other (Litten et al. 1995, Helander et al. 1996) and may, thus, 
reflect different drinking patterns. For men, CDT levels respond to number of days 
drinking, whereas GGT responds to drinks per drinking day. For women, both CDT and 
GGT were influenced more by drinks per drinking day than by number of days drinking 
(Anton et al. 1998).  However, although widely used, neither GGT nor CDT is sensitive 
and specific enough to determine the degree of alcohol abuse or its medical complications 
(Niemelä 2007). GGT and CDT may be combined as the marker gamma-CDT ( = 0.8 * ln 
(GGT) + 1.3 * ln (CDT)), which appears to show better sensitivity, specificity and a 
stronger correlation with the amount of alcohol intake than other markers (Hannuksela et 
al. 2007). New biomarkers that may possibly gain foothold in clinical work in the future 
include phosphatidylethanol, fatty acid ethyl esters, ethyl glucuronide, sialic acid, and 
acetaldehyde adducts (Hannuksela et al. 2007).  
 
2.5.2. Effects of ethanol on cardiovascular disease 
 
Several studies have shown that moderate consumption of alcohol reduces mortality from 
vascular diseases (Doll 1997) and reduces the risk of atherosclerosis (Kannel and Ellison 
1996).  There seems to be a J-shaped association between alcohol consumption and 
coronary heart disease incidence events (Moore and Pearson 1986, Langer et al. 1992). A 
recent study suggests that the cardiovascular benefits that may be derived from light-to-
moderate alcohol consumption are not mediated through reduced calcium accumulation 
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(McClelland et al. 2008). Alcohol intake may reduce blood coagulation (Gorinstein et al. 
1997). Moderate alcohol consumption is associated with lower levels of several 
coagulation factors, namely fibrinogen, factor VII and von Willebrand factor (Lee and Lip 
2003). On the other hand, excessive alcohol use and alcoholism have detrimental effects 
on the cardiovascular system and are associated with increased occurrence of stroke, 
abdominal aneurysms, hypertension, alcoholic cardiomyopathy, arrhythmias, as well as 
increased CHD (Regan 1990, Ahlawat and Siwach 1994, Klatsky 1987, Knochel 1983, 
Lip and Beevers 1995).  
 
2.5.3. Effects of ethanol on the metabolism of lipids and lipoproteins 
 
Ethanol has effects on lipoprotein metabolism in several different phases: acetate formed 
from ethanol acts as a substrate in hepatic triglyceride synthesis, it modulates 
apolipoprotein synthesis and the activity of the central enzymes of lipoprotein metabolism 
(ie. lipoprotein lipase, hepatic lipase, cholesteryl ester transfer protein and phopholipid 
transfer protein) (Hannuksela et al. 2004). Furthermore, ethanol may increase insulin 
sensitivity (Avogaro et al. 2004). Acetaldehyde, as well as antioxidative reagents found in 
some alcohol beverages, modify lipoproteins (Frohlich 1996). The unfavorable effects of 
alcohol on lipoprotein metabolism include hypertriglyceridemia and fatty liver, and in the 
later phase, hypercholesterolemia and decreased HDL cholesterol (Sabesin 1981). 
The beneficial effects of alcohol may partly be mediated by its effects on 
lipoprotein metabolism, since moderate alcohol consumption has generally been 
associated with an increase of HDL cholesterol (Glueck 1985, Angelico et al. 1982) and a 
decrease of LDL cholesterol (Kervinen et al. 1991). Moderate alcohol consumption 
stimulates apolipoprotein AI secretion by hepatocytes and alters enzymatic activity of 
several plasma proteins and enzymes involved in lipoprotein metabolism (Hartung et al. 
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1990, Amarasuriya et al. 1992, Clevidence et al. 1995, Hannuksela et al. 2002). The 
increase in HDL cholesterol appears to account for approximately half of alcohol's 
cardioprotective effect (Langer et al. 1992, Hannuksela et al. 2002). Furthermore, 
environmental and genetic factors may modulate the effects of ethanol on plasma lipids. 
These include type of alcoholic beverage, lifestyle, drinking pattern, smoking, diet, 
exercise, liver disease, gender, apoE and cholesteryl ester transfer protein genotype 
(Hannuksela et al. 2002, Hannuksela and Savolainen 2001).  
The alcohol-induced increase in HDL cholesterol has been usually taken as an 
indicator of a high rate of RCT from peripheral tissues to the liver (Barter et al. 2003). 
However, HDL are heterogeneous populations of lipoprotein particles (HDL2, HDL3). 
The increased cholesterol efflux potential of HDL2 may be the anti-atherogenic feature of 
RCT linked to heavy alcohol consumption (Mäkelä et al. 2008). The effects of alcohol 
intake on different HDL subclasses are variable (Hannuksela et al. 2002, Sillanaukee et al. 
1993a). Chronic alcohol intake appears to have a raising effect on HDL2 cholesterol and 
lipase activities in both men and women. The protein concentration in HDL2 is increased, 
while the HDL3 protein concentration is often unchanged in alcoholics. That is why 
chronic alcohol intake results in a shift towards larger, less dense HDL2 particles. Alcohol 
withdrawal is associated with a shift to smaller HDL3 particles (Hannuksela et al. 2004). 
However, there is evidence that larger HDL particles predict the capacity of HDL particles 
to accept cholesterol from macrophages (Fournier et al. 1997, Matsuura et al. 2006, 
Vikstedt et al. 2007). Recent advances in lipoprotein research have shown that in addition 
to its role in RCT, HDL has multiple anti-atherogenic functions such as anti-infectious, 
anti-thrombotic, anti-oxidative and anti-apoptotic activity. HDL is also important in 
endothelial repair and increases vasodilatation (Assmann and Gotto 2004, Hannuksela et 
al. 2004, Ansell et al. 2006).  
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3. AIMS OF THE STUDY 
 
1) To investigate possible effects of postmenopausal hormone replacement therapy on the 
oxidation of LDL and progression of cardiovascular diseases [I]. 
 
2) To look for associations between the genotype of estrogen receptor 1 and progression 
of cardiovascular diseases in postmenopausal women [II]. 
 
3) To study the effects of alcohol consumption on plasma lipid profile in relation to 
laboratory biomarkers of alcohol use. These topics were first studied in a pilot study of a 
group of 70 men [III] and subsequently in a large population study [IV]. 
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4. SUBJECTS, MATERIALS AND METHODS 
 
4.1. Subjects 
 
4.1.1 Women from annual routine gynecological examinations (I, II) 
 
Women attending a private outpatient clinic in Tampere for annual routine gynecological 
examinations were invited to participate. For the cross-sectional baseline study in 1993 
(Punnonen et al. 1995), 141 non-smoking, non-diabetic postmenopausal women aged 45–
71 years were enrolled. They had no clinically evident CVD or hypertension and were 
classified into four groups based on the monthly use of HRT. The HRT-EVP group (n=40) 
used estradiol valerate (EV) 2 mg per day for 11 days followed by EV continued with 
progestin (P, levonorgestrel 0.25 mg per day) for 10 days. The HRT-EVM group (n=21) 
used estradiol valerate (EV) 2 mg per day for 11 days followed by EV continued with 
progestin (M, medroxyprogesterone acetate 10 mg per day) for 10 days. The HRT-EV 
group (n=40) used EV alone, and the control group (n=40) had never used HRT. In HRT-
EVP, HRT-EVM and HRT-EV groups there was a pause of therapy for 7 days after each 
21-day cycle. Of these 141 women 91 (60 in HRT group, 31 controls) participated in 5-
year follow up study from 1993 to 1998. HRT, when used, was started at the time of 
menopause for climacteric symptoms. In the control group, the main reasons not to use 
HRT were the absence of vasomotor and other climacteric symptoms and dislike of HRT. 
The mean duration of EVP and EVM was 9.3±3.2 years and of EV treatment 9.9±4.2 
years at the beginning of the study. The mean time from menopause in the control group 
was 11.9±4.1 years (mean 9.9±3.8 years, at baseline). The mean ages in the HRT-EVP, 
HRT-EVM, HRT-EV, and control groups were 59.6±4.7, 55.9±3.4, 61.0±5.0, and 
61.6±5.5 years, respectively (P=0.0002 over all groups in analysis of variance, ANOVA). 
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The mean body mass indexes were (BMI, mean 25.3±3.2 kg/m2) similar in all studied 
groups (P=0.8941 over all groups in ANOVA). In the HRT-EV, HRT-EVP, and control 
groups 24, 4, and 6 women underwent hysterectomy, respectively, due to benign 
conditions and 4, 2, and 2 women bilateral salpingo-oophorectomy. At baseline, all 
women were clinically healthy, and used no chronic medication. Nutrient intake analyses 
were also performed, as described elsewhere (Punnonen et al. 1995), and these analyses 
did not show any marked differences between the study groups in the amount of used 
saturated, monounsaturated, and polyunsaturated fats, or dietary cholesterol. Sonography 
and blood sampling were done in the University Hospital of Tampere. The Ethics 
Committee of the University Hospital of Tampere approved the study. 
 
4.1.2. Men from an occupational health survey (III) 
 
Alcohol and lipid profile-related laboratory tests were carried out in 70 consecutive non-
alcoholic male employees (mean age 45 years, range 37-58 years, SE 0.7 years) in 
connection with an occupational health survey in 1996. The employees were both blue-
collar and white-collar workers from a board machine manufacturing factory.  
 
4.1.3. Men and women from the 1997 Finrisk study (IV) 
 
The National Public Health Institute of Finland has performed large cross-sectional 
population surveys, the FINRISK studies, related to the risk factors of CAD every 5 years 
beginning in 1972 (Puska et al. 1995). The 1997 FINRISK study was conducted in five 
geographic areas: Helsinki–Vantaa region in Southern Finland, Turku–Loimaa region in 
Southwestern Finland, Kuopio and North Karelia provinces in Eastern Finland, and Oulu 
province in Northern Finland. In each study area, an age- and gender-stratified random 
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sample of 2000 subjects was drawn from the population aged between 25 and 64 years. In 
addition, a random sample of 500 men and 250 women was drawn in Helsinki–Vantaa 
region and in North Karelia province from the 65–74 years age-group.  
Our study was a sub-study of the 1997 FINRISK project. The total sample size was 
11500. The participation rate was 71 % among men and 76 % among women. Subjects 
who had missing data on serum lipids, GGT or CDT, who had diabetes, who were 
pregnant or who were using cholesterol lowering medication or hormonal treatment were 
excluded. Thus, 3097 males and 2578 females were included in the study. The study was 
conducted according to the Helsinki Declaration of 1975 on Human Experimentation and 
was approved by the Ethical Committee of Primary Health Clinics in Finland. All 
participants gave informed consent to scientific use of the data and samples collected in 
the study. 
 
4.2. Blood samples (I-IV) 
 
Blood samples were taken after the subjects had fasted overnight (I-III), or at least 4 hours 
(IV). After separation of serum by low-speed centrifugation the sera were divided into 
aliquots and stored at −70°C until analyzed. 
 
4.2.1. Lipid analyses (I-IV) 
 
In studies I and II serum total cholesterol and triglycerides were determined by 
commercial methods (Kodak Echtachem 700XR, Eastman Kodak Company, Clinical 
Products Division, Rochester, USA). Serum HDL cholesterol was separated by a dextran–
sulfate–Mg precipitation procedure (Nquven 1989) and the cholesterol content was 
analyzed with a Monarch 2000 Analyzer (Instrumentation Laboratory, Lexington, USA), 
 37 
using the CHOD-PAP cholesterol reagent (Cat No. 237574; Boehringer Mannheim, 
Germany) and a primary cholesterol standard (Cat No. 530; Orion, Finland). The LDL 
cholesterol concentration was calculated according to the Friedewald formula (Friedewald 
1972). Apolipoproteins (apo) A1 and B were determined on a Monarch Analyzer by an 
immunoturbidimetric method (Riepponen 1987) (Cat No. 67265 and 67249, Orion 
Diagnostics, Finland). In the 5-year follow-up study the lipid concentrations were 
determined with Cobas Integra 700 analyzer with reagents and calibrations recommended 
by the manufacturer (Hoffmann-La Roche Ltd., Basel, Switzerland). In studies III and IV, 
total and HDL cholesterol were determined from fresh serum samples using CHOD-PAP. 
Triglycerides were measured by a fully enzymatic method (GPO-PAP, Boehringer-
Mannheim). 
 
4.2.2. Determination of autoantibodies against oxLDL (I) 
 
Antigens for this assay included: (A) native LDL prepared from the pooled plasma of ten 
donors and protected against oxidation by 0.27 mmol/l EDTA and 20 mol/l butylated 
hydroxytoluene (BHT) in phosphate buffered saline (PBS); and (B) oxidized LDL 
obtained after 24-h oxidation of the native LDL with 2 mol/l CuSO4. For enzyme-linked 
immunosorbent assay, half of the wells on a polystyrene plate (Nunc, Roskilde, Denmark) 
were coated with 50 µl of native and the other half with 50 µl copper-oxidized LDL 
antigen (both at a concentration of 5 g/ml) in PBS for 16 h at 4°C. After removal of the 
unbound antigen and washing of the wells, the remaining non-specific binding sites were 
saturated using 2% human serum albumin (HSA) in PBS and 20 mol/l BHT for 2 h at 
4°C. After washing, 50 µl of the serum samples, diluted 1:20, were added to wells coated 
with native LDL and oxidized LDL and incubated overnight at 4°C. After incubation the 
wells were aspirated and washed six times before an IgG-peroxidase conjugated rabbit 
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anti-human monoclonal antibody (Organon, USA No. 55220 Cappel), diluted 1:4000 (v/v) 
in buffer (0.27 mmol/l PBS, 20 mol/l EDTA, 1% BHT, 0.05% Tween HSA), was added to 
each well for 4 h at 4°C. After incubation and washing, 50 µl of freshly made substrate 
(0.4 mg/ml o-phenylenediamine (Sigma) and 0.045% H2O2 in 100 mmol/l acetate buffer, 
pH 5.0) was added and incubated exactly 5 min at room temperature. The enzyme reaction 
was terminated by adding 50 µl of 2 M H2SO4. The optical density (OD) was measured at 
492 nm using a microplate reader. All measurements were blinded and done on coded 
serum samples. The results were expressed as the mean OD values from duplicate 
determinations, and autoantibody titer against oxidized LDL was calculated by subtracting 
the binding of antibodies to native LDL from that to copper-oxidized LDL. This approach 
reduces the possibility of getting false positive values due to cross-reactivity with both 
LDL epitopes.  
 
4.2.3. DNA extraction and ESR1 genotyping (II) 
 
DNA was isolated from white blood cells using a commercial kit (Qiagen Inc, CA). A 
region of the ESR1 gene containing a part of intron one and exon two was amplified using 
primary and secondary (nested) primers designed from those reported by Yaich et al. 
(Yaich 1992). After digestion of the PCR product with PvuII restriction endonuclease, 
fragments were separated using agarose gel (1.0%) electrophoresis. Capital (P, mutated) 
and small (p, wild type) letters denoted the absence and presence of the restriction sites, 
respectively. 
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4.2.4. Determination of serum CDT and GGT (III, IV) 
 
CDT concentrations in serum samples were analyzed by a double antibody kit (CDTect™, 
Pharmacia and Upjohn Diagnostics, Uppsala, Sweden) according to the manufacturer's 
instructions. The test is based on anion exchange chromatography and radioimmunoassay 
(Stibler 1991, Stibler et al. 1986) and has a detection limit of 1 U/l and a measuring range 
of 5–300 U/l. The calibration of the test was assessed from a five-point standard curve 
derived from the displacement of 125I-CDT from the antibody by known amounts of 
human transferrin, within the interval 0–100 U/l. CDTect gives the results in units per 
liter, which is comparable to mg/l in serum (1 U CDT refers to ≈1 mg transferrin). The 
reference values for CDT (CDTect™) were <20 units/L for men and <26 units/L for 
women. The activity of serum GGT (reference value <80 IU/L for men and <50 IU/L for 
women) was determined according to the recommendations of the Scandinavian Society 
for Clinical Chemistry and Clinical Physiology (1976).  
 
4.3. Sonography (I-II) 
 
Sonography at baseline and follow-up were performed with Toshiba Sonolayer V SSA 
100 equipment, as reported elsewhere (Punnonen et al. 1995). Briefly, all the sonographies 
were done blinded by one experienced sonographer and radiologist. During the 
examinations women were lying in a supine position. Transverse and longitudinal scans of 
extracranial carotid arteries were performed bilaterally at four different segments of the 
carotid: first, at the 10 mm segment of the common carotid artery (CCA) just distal to the 
origin of carotid bifurcation, second at a 10 mm segment in the area of distal third of the 
CCA, third at the 10 mm segment between origin of carotid bifurcation and the tip of the 
flow divider, which separates internal from external carotid arteries, and fourth at a 10 
 40 
mm segment of the internal carotid artery cranial from flow divider. Only fibrous and 
calcified atherosclerotic lesions were considered and were defined as plaques when 
distinct areas of mineralization or/and focal protrusion into the lumen were identified. The 
thickness and length of such plaques within the artery vessel wall were determined by 
transverse and longitudinal scans, respectively, and the thickness of a plaque was 
determined as the distance between the intimal–luminal interface and the medial–
adventitial interface. The intimal–medial far-wall thickness equal to or more than 1.3 mm 
at any segment in carotid arteries was defined as an atherosclerotic plaque (Furberg et al. 
1989) and the total number of plaques was calculated. All carotid artery sonographies 
were done with a 5.0 MHz convex transducer probe. 
Longitudinal sonographs of the abdominal aorta were obtained at 1 cm intervals 
and transverse scans at 2 cm intervals at the area of three aortic segments: (1) supra-
pancreatic; (2) pancreatic and infra-pancreatic; and (3) at the area of the aortic bifurcation. 
As for carotid plaques, significant aortic plaques were defined as an intimal–medial far-
wall thickness equal to or more than 3.0 mm (Furberg et al. 1989). All aortic examinations 
were performed using a 3.75 MHz convex transducer probe. The average duration for the 
whole examination varied from 25 to 30 min. 
The atherosclerotic severity sum (AS) was constructed by dividing the 
atherosclerotic changes of abdominal aorta and carotid arteries into three severity classes: 
1=slight, 2=moderate, and 3=severe, and calculating the sum, i.e. AS. Total number of 
atherosclerotic plaques (NAP) was subsequently calculated. 
The reproducibility of the sonographic protocol for significant aortic and carotid 
plaques was also examined: 1 month after the first assessment 20 randomly selected 
subjects were invited to a repeated examination. The reproducibility of the number of 
plaques (number of plaques initial by repeated sonography) between the first and second 
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examination was 90% for the carotid artery segment areas and 100% for the aortic 
segments. 
 
4.4. Estimation of alcohol intake (III) 
 
Estimation of the alcohol intake was carried out by Alcohol Use Disorders Identification 
Test (AUDIT) by WHO (Saunders et al. 1993, Seppä et al. 1995). 
 
4.5. Quantitative estimation of alcohol intake, smoking and physical activity (IV) 
 
Quantitative estimation of alcohol intake was carried out by using 12 structured questions 
to determine the amount and frequency of drinking. The measure for average weekly 
intake included the following drinks: beer, cider, liquor, long drink and wine. The total 
mean consumption of all alcoholic drinks was expressed as grams of pure ethanol per 
week. The variable ‘number of smokes per day’ was computed by adding up the numbers 
of filter cigarettes, non-filter cigarettes, self-made cigarettes, pipe-fulls and cigars smoked 
on an average day for all subjects who reported having smoked within 1 month prior to 
the survey. ‘Physical activity’ was determined as a session of leisure-time exercise 
resulting in shortness of breath and sweating (times/week). 
 
4.6. Statistical analyses (I-IV)  
 
All calculations were done with the Statistica for Windows version 5.1 (Statsoft Inc., 
Tulsa, Oklahoma, USA) software in PC. P-values of less than 0.05 were considered 
statistically significant. 
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In study I, two-way analysis of covariance (using age, BMI, and total cholesterol as 
covariates, when appropriate) was used to assess the interaction between grouping factor, 
HRT groups and control group, in selected variables of interest (=dependent variables) i.e. 
AS, total NAP, serum lipids, and apolipoproteins. Two- and one-way ANOVA was used 
to assess the statistical differences between HRT groups and control group in lipid 
parameters. Age and BMI were used as covariates when appropriate. Pairwise 
comparisons of group means were done by using ANOVA, age and BMI as covariates, 
when appropriate. Multiple regression was used in search for the variables that predict the 
severity of atherosclerosis. Repeated measures ANOVA was used to study the effect of 
time and HRT on AS in our study population.  
In study II, two-way ANOVA was used to assess the interaction between ESR1 
PvuII genotype groups and treatment groups. One-way ANOVA was used to assess the 
statistical differences between HRT groups and control group and among ESR1 PvuII 
genotypes in lipid parameters. Repeated measures ANOVA was used to study the effect of 
time, ESR1 PvuII genotype and HRT on AS in the study population.  
In studies III and IV, subjects were divided into quartiles on the basis of CDT 
concentration or GGT activity. Estimated significance was based on ANOVA.  
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5. RESULTS 
 
5.1. Effects of postmenopausal hormone replacement therapy on oxidation of LDL 
and progression of cardiovascular diseases in a 5-year follow up (I) 
 
The purpose of the study was to determine whether HRT has a beneficial attenuating 
effect on sonographically determined NAP and AS in the CCA and abdominal aorta of 
101 postmenopausal women compared to 40 controls without HRT. The interaction of 
HRT and antibodies against oxidized LDL on AS and NAP progression was also studied.  
The HRT-EVP group used estradiol valerate (EV) followed by EV continued with 
progestin (P, levonorgestrel), the HRT-EVM group used EV followed by EV continued 
with progestin (M, medroxyprogesterone acetate), the HRT-EV group used EV alone, and 
the control group had never used HRT. During the 5-year follow-up, the concentration of 
HDL cholesterol increased and LDL cholesterol decreased significantly in HRT-EV, 
HRT-EVP and control groups, and total cholesterol decreased significantly in the HRT-
EV group and controls, but not in the HRT-EVP group. The triglycerides increased in 
HRT-EVP group and controls but not in the HRT-EV group. The HRT-EVM group was 
not included in the lipid follow-up. 
HRT-EV, HRT-EVP and HRT-EVM therapies were each associated with lower 
AS and NAP as compared to controls without HRT. AS was significantly higher in both 
the HRT groups and control group after follow-up, compared to baseline. In a multiple 
regression model explaining NAP in the whole study population, the strongest predictors 
were HRT (P=0.0006) and copper-oxidized LDL autoantibodies (P=0.0491). What comes 
to oxLDL autoantibodies, it was evident that they seem to predict NAP in postmenopausal 
women, but do not seem to affect AS at least during the 5-year follow up time (Figure 4 = 
Figure 2 from I). 
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Figure 4. Scatterplot of oxidized LDL antibody titer on X-axis and number of 
atherosclerotic plaques on Y-axis.  
 
In conclusion, the findings indicated that both estradiol valerate alone, combined 
estradiol valerate–levonorgestrel, and combined estradiol valerate–medroxyprogesterone 
acetate therapy are associated with lower total NAP and less severe atherosclerotic 
lesions, as compared to controls without HRT. This outcome may also be associated with 
a reducing effect of HRT on LDL oxidation. 
 
5.2. Associations between the genotype of estrogen receptor and progression of 
cardiovascular diseases in a 5-year follow up (II) 
 
At baseline, the mean age, BMI, total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, apoA1 and apoB were not significantly different among the genotypes. 
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Subjects with the P/P genotype had a higher AS (1.93 ±/0.92) as compared with P/p (1.24 
±/0.85) and p/p (1.43 ±/0.84) genotypes (P=0.012). 
  ESR1 PvuII genotype, HRT treatment and time had a statistically significant or 
borderline significant effect on AS during 5-year follow-up (P=0.090, P=0.004 and 
P<0.001, respectively), when analyzed by repeated measures ANOVA (Figure 5 = Figure 
1 from II).  
 
Figure 5. The main effect of ESR1 PvuII genotypes, HRT, and time on atherosclerotic 
severity score during 5-year follow-up analyzed by repeated measures ANOVA. ESR1 
PvuII, estrogen receptor 1 PvuII; HRT, hormone replacement therapy. EV, estradiol 
valerate, 2.0 mg/day; P, levonorgestrel, 0.25 mg/day. Atherosclerotic severity score is 
estimated from aorta and carotid artery by sonography. Age was used as covariate. 
 
There was a significant genotype-by-treatment (HRT-EVP and control groups) 
interaction for AS (P=0.034). In response to HRT-EVP, subjects homozygous for the 
mutated forms of the receptor P/P, compared with those with P/p and p/p genotypes, had 
less increase in AS (1.60 ± 1.14 vs. 1.71 ± 1.27 vs. 2.43 ± 1.27). Baseline AS as covariate 
in similar model did not change the significant interaction effect between HRT-EVP and 
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control groups (P=0.036). However, this effect was not found between HRT-EV and 
control groups (Table 1). The results suggest that the effect of HRT-EVP in 
postmenopausal women on progression of AS may be determined in part by the genotype 
of ESR1 PvuII.  
 
HRT HRT-EVP HRT-EV Controls (no HRT) 
Genotype 
(n) 
P/P 
(5) 
P/p 
(14) 
p/p 
(7) 
P/P 
(3) 
P/p 
(19) 
p/p 
(10) 
P/P 
(6) 
P/p 
(13) 
p/p 
(11) 
Baseline 
(SD) 
1.80 
(0.84) 
1.14 
(0.95) 
1.29 
(0.49) 
1.33 
(1.53) 
1.11 
(0.66) 
1.10 
(0.88) 
2.33 
(0.52) 
1.54 
(0.97) 
1.82 
(0.87) 
Follow-up 
(SD) 
3.40 
(1.67) 
2.86 
(1.35) 
3.71 
(1.11) 
3.67 
(2.08) 
3.00 
(1.33) 
2.50 
(1.18) 
5.33 
(1.75) 
4.31 
(1.93) 
3.73 
(1.56) 
Change 
(SD) 
1.60 
(1.14) 
1.71 
(1.27) 
2.43 
(1.27) 
2.33 
(0.58) 
1.89 
(1.37) 
1.40 
(0.84) 
3.00 
(1.67) 
2.77 
(1.30) 
1.91 
(1.14) 
 
Table 1: Baseline and follow-up AS according to ESR1 PvuII genotypes and HRT groups. 
HRT, hormone replacement therapy; EVP, estradiol valerate and progestin; EV, estradiol 
valerate alone; P, mutated ESR1 PvuII receptor gene; p, wild type ERS1 PvuII receptor 
gene. 
 
It is interesting to notice that P/p genotype seemed at baseline to be related to less 
severe atherosclerosis, and was thus the most beneficial in regard to the development of 
atherosclerosis. If both alleles were mutated, the severity of atherosclerosis seemed to be 
increased at baseline. These two findings were trends without statistical significance. 
Statistically significantly, in the HRT-EVP group, the more mutated alleles the person 
had, the more she gained benefit of HRT. However, the severity of atherosclerosis 
increased the most in women with wild-type (p/p) receptor alleles. Interestingly, the trend 
was just the opposite in HRT-EV group without progestin component, as the wild-type 
(p/p) receptor carriers seem to benefit the most from estrogen replacement therapy. The 
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same trend of atherosclerosis progression were seen in both HRT-EV and  control groups, 
as the presence of mutated receptor alleles (P/p and P/P) seemed to be associated with 
increased AS progression.  
In conclusion, one could say, the more mutated ESR1 PvuII alleles a person has, 
the more she benefits of combined estrogen-progesterone HRT. The same cannot be said 
about estrogen-only therapy. In HRT-EV and controls, the wild-type receptor gene seemed 
to be beneficial in regard to atherosclerosis progression. This may have clinical relevance, 
and it would be possible to evaluate beforehand the benefit of considered HRT based on 
the ESR1 PvuII genotype. 
 
5.3. Effects of alcohol consumption on the lipid profile (III, IV) 
 
When the men from the occupational health survey (III) were divided into quartiles 
according to CDT and GGT, the men in the highest CDT quartile had significantly higher 
serum HDL cholesterol concentration than those in the lowest quartile. The men in the 
highest GGT quartile had significantly higher serum total cholesterol, lower serum HDL 
cholesterol, higher serum LDL cholesterol and higher serum triglyceride concentration 
than the lowest quartile (Figure 6 = Figure 1 from III).  
The results obtained from study III were further confirmed in a larger population, 
in both genders (Table 2; Figure 7, panels A and B). Serum CDT concentrations were 
positively associated with higher alcohol consumption and smoking and lower BMI in 
both genders in the FINRISK-study (IV). There was no significant difference in physical 
activity between the different CDT quartiles. Serum CDT concentrations were negatively 
associated with age in women, but not in men. Serum HDL cholesterol values were 
significantly higher and triglycerides lower with increasing serum CDT concentrations for 
both men and women. These results remained significant even after adjustment for age, 
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BMI and smoking. Serum total cholesterol decreased with increasing CDT concentrations 
in women, but not in men. However, this was not significant after adjustment for age, 
BMI and smoking. Serum CDT concentration and GGT activity were positively associated 
in men and negatively associated in women, but the negative association in women did not 
remain significant after adjustment for age, BMI and smoking. 
 
 
Figure 6.  Cholesterol, HDL-cholesterol and triglycerides (mmol/l) in the lowest (1) and 
highest (4) CDT and GGT quartiles. CDT quartiles: lowest ≤12U/L, highest ≥16U/L. 
GGT quartiles: lowest < 29U/L, highest ≥75U/L. The larger box, ±1.00 SE; the vertical 
lines, ±1.96 SE; the small box, mean. Elevated CDT seems to have positive effects on  
lipid values, whereas elevated GGT seems to have adverse effects on them. Statistical 
significance *, p<0.05; **, p< 0.01; ns, not significant. 
 
It appears that increased CDT is associated with a favorable lipid profile, including 
higher HDL cholesterol and lower triglycerides. In contrast, increase in GGT quartiles 
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appeared to affect the lipid profile unfavorably. There were higher concentrations of total 
cholesterol and triglycerides for both genders with increasing GGT activity.  
Since serum CDT concentration and GGT activity seemed to have contrasting 
associations with lipid biomarkers for cardiovascular risk, a comparison was made 
between the lipid values in subjects who had a highest quartile CDT and a lowest quartile 
GGT (CDT Q4/GGT Q1) or a lowest quartile CDT and a highest quartile GGT (CDT 
Q1/GGT Q4) (IV). The CDT Q4/GGT Q1 group had significantly lower cholesterol and 
triglyceride values and higher HDL cholesterol values than the unfavorable CDT Q1/GGT 
Q4 group in both genders, even after adjustment for age and BMI (Table 2; Figure 7, 
panels A and B). 
 
 
Men 
CDT Q1 / GGT Q4 
(n=178) 
CDT Q4 / GGT Q1 
(n=180) 
Significance 
adjusted to  
age and BMI 
Total cholesterol 5.90 (1.14) 5.19 (0.98) p<0.001 
HDL cholesterol 1.11 (0.28) 1.42 (0.31) p<0.001 
Triglycerides 2.35 (1.35) 1.12 (0.49) p<0.001 
Alcohol last week 89.9 (109) 80.0 (94.1) ns 
 
 
Women 
CDT Q1 / GGT Q4 
(n=194) 
CDT Q4 / GGT Q1 
(n=223) 
Significance 
adjusted to  
age and BMI 
Total cholesterol 5.90 (1.09) 5.06 (0.97) p<0.05 
HDL cholesterol 1.36 (0.33) 1.62 (0.31) p<0.001 
Triglycerides 1.84 (1.41) 0.89 (0.37) p<0.001 
Alcohol last week 22.9 (42.2) 28.0 (38.4) ns 
 
Table 2. Lipid values (mmol/l (S.D.)) and alcohol consumption during last week (g 
(S.D.)) of subjects belonging to the opposite extreme quartiles of CDT and GGT. 
CDT, carbohydrate-deficient transferrin; HDL, high density lipoprotein; GGT, gamma-
glutamyl transferase; Q, quartile; ns, not significant. 
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Figure 7. Serum lipid concentrations according to CDT and GGT quartiles in men (panel 
A) and women (panel B). Significance adjusted by age and BMI is displayed by * symbol. 
Statistical significance *, p<0.05; **, p< 0.01; ***, p<0.001. Values as mmol/l. 
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As a curiosity, in our data of the Finrisk study 1997, gamma-CDT seemed to be a 
more sensitive marker of alcohol use compared to either GGT or CDT (unpublished data 
from Finrisk study 1997). The correlations of alcohol markers CDT, GGT and gamma-
CDT to alcohol use during the previous week are shown in Table 3 below.  
 
MEN (n=3682) Mean (S.D.) Correlation Significance 
GGT 45.6 (75.1) 0.28 p<0.05 
CDT 14.8 (6.61) 0.31 p<0.05 
Gamma-CDT 6.24 (0.71) 0.40 p<0.05 
Alcohol last week 82.1 (120)   
 
WOMEN (n=2864) Mean (S.D.) Correlation Significance 
GGT 25.3 (38.0) 0.17 p<0.05 
CDT 18.4 (6.71) 0.26 p<0.05 
Gamma-CDT 6.13 (0.57) 0.26 p<0.05 
Alcohol last week 27.9 (48.1)   
 
Table 3: Correlation of alcohol markers GGT (IU/L (S.D.)), CDT (U/L (S.D.)) and 
gamma-CDT ( = 0.8 * ln (GGT) + 1.3 * ln (CDT)) to alcohol use (g (S.D.)) during the 
previous week. CDT, carbohydrate-deficient transferrin; GGT, gamma-glutamyl 
transferase. 
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6. DISCUSSION 
 
6.1. Postmenopausal HRT is associated with less severe atherosclerotic lesions and 
diminished LDL oxidation (I) 
 
Our findings indicated that estradiol valerate alone, combined estradiol valerate–
levonorgestrel, and combined estradiol valerate–medroxyprogesterone acetate therapy are 
associated with lower total NAP and less severe atherosclerotic lesions, as compared to 
controls without HRT, and that this outcome may be associated with the reducing effect of 
HRT on LDL oxidation. In the present study, during the 5-year follow-up, the 
concentration of HDL cholesterol increased and LDL cholesterol decreased in HRT 
groups, in agreement with previous studies (Koh and Sakuma 2004). Several previous 
studies have shown that postmenopausal estrogen therapy reduces the risk of CVD 
(Barrett-Connor and Bush 1991, Kannel et al. 1976, Stampfer and Colditz 1991, Stampfer 
et al. 1991). In a recent study, postmenopausal women on estrogen therapy had 
significantly fewer coronary calcifications than those on placebo (Manson et al. 2007).  
However, in some studies no beneficial effect (Rosenberg et al. 1976), and even an 
adverse effect and increase in the incidence of CVD (Gordon et al. 1978), have been 
reported to be associated with HRT. Furthermore, during recent years, the WHI (Writing 
Group for the Women's Health Initiative Investigators 2002, Rossouw et al. 2002), Heart 
Estrogen/progestin Replacement Study (HERS) (Grady et al. 2002) and Million Women’s 
study (Million Women Study Collaborators 2003) have indicated that HRT increases the 
risk for stroke, breast cancer and possibly also dementia. Even more recent results from 
the WHI showed that estrogen plus progestin may increase the risk of CVD among 
postmenopausal women, especially during the first year after the initiation of hormone use 
 53 
(Manson et al. 2003). However, subsequent publications with more detailed analyses 
appear to have reversed these initial concerns (Stevenson et al. 2009).  
HERS found no overall reduction in risk of CHD events among postmenopausal 
women with CHD (Grady et al. 2002). Participants were randomly assigned to receive 
either conjugated estrogens and medroxyprogesterone acetate, or placebo. However, in the 
hormone group, findings did suggest a higher risk of CHD events during the first year, and 
a lower risk during years 3 to 5. Lower rates of CHD events among women in the 
hormone group in the final years of HERS did not persist during additional years of 
follow-up. After 6.8 years, hormone therapy did not reduce risk of cardiovascular events 
in women with CHD (Grady et al. 2002). In this study, however, estrogen receptor 
genotype was not considered, and it would be interesting to reevaluate whether there is a 
genetic subgroup that benefits more from HRT. 
In the present study, the level of oxidized LDL autoantibodies seemed to predict 
the NAP in postmenopausal women. It is important to note that the subjects had already 
used HRT for almost 10 years at the beginning of the study. In the study of Heikkinen et 
al. (1998), a 1-year combined estrogen–progestogen treatment was not effective in 
changing the oxidized LDL autoantibody titer, regardless of the beneficial effects on 
serum lipid parameters. It has been suggested that the antioxidative effect of estradiol may 
be anti-atherogenic by reducing the likelihood of oxidative modification of LDL, and thus 
preventing lipid accumulation within blood vessel walls and foam-cell formation (Sugioka 
et al. 1987, Ylä-Herttuala et al. 1996). There is in fact in vitro evidence that estrogens 
inhibit oxidative modification of LDL (Maziere et al. 1991, Badeau et al. 2005), which is 
believed to be one of the early events involved in the progression of atherosclerosis. 
Antioxidant protection provided by estrogens are free radical scavenging, chelating of 
ions, and importantly stabilizing the conformation of apoB-100, the major apolipoprotein 
of LDL, to be resistant to oxidation (Brunelli et al. 2000). 
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6.2. The effect of HRT on progression of atherosclerosis may be determined in part 
by the genotype of estrogen receptor (II) 
 
Both long-term HRT and ESR1 PvuII genotype have affected the progression of 
atherosclerosis in postmenopausal women during a 5-year follow-up. Subjects with 
estradiol-valerate-levonorgestrel therapy and P/P genotype had less increase in AS, 
compared with those with P/p and p/p genotypes. All subjects in this study were non-
smokers, nondiabetics, had normal blood pressure, and were also otherwise clinically 
healthy. The dietary analysis did not reveal any substantial differences in the use of 
saturated vs. polyunsaturated fat or dietary cholesterol between the HRT groups 
(Punnonen et al. 1995). Some other factors that may differ between HRT users and non-
users (i.e. socioeconomic status, family history) were not accounted for and may have 
biased our results. There was also a small number of participants in the study. 
In randomized clinical trials, estrogen has not been shown to slow down the 
progression of atherosclerosis (Hulley et al. 1998, Herrington 1999). In these studies, 
however, the possible genotypic effects on HRT response were not considered. Therefore, 
it would be interesting to perform a reanalysis of previous negative trials (Hulley et al. 
1998, Herrington 1999) to find out whether there is a genetic subgroup, which would 
benefit more from HRT than other groups. The mechanism behind the ESR1PvuII 
polymorphism that affects signalling via ESR1 is not known, but the variant forms are 
strongly associated with the area of advanced atherosclerotic lesions (Lehtimäki et al. 
2002). 
The results suggest that women with the PvuII genotype P/P (presently referred to 
by C/C) of the  c.454-397T>C benefit most from estrogen replacement therapy. The same 
CC genotype has earlier been found to be significantly associated with CAD in the 
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Helsinki Sudden Death study (Lehtimäki et al. 2002). The Framingham Heart Study has 
confirmed that the CC genotype is associated with enhanced progression of 
atherosclerosis. Men with the CC genotype had a substantial increase in risk of MI 
compared with the TT and CT genotypes (Shearman et al. 2003). Thus the variations in 
the ESR1 gene may affect the action of estrogen on the artery wall, and the effect of HRT 
on progression of atherosclerosis.  
These results and those of others thus stress the importance of estrogen receptor 
genotype and suggest that estrogen receptor genotype has potential to explain recent 
conflicting data on estrogen replacement therapy and CVD susceptibility in women 
(Rossouw et al. 2002).  
 
6.3. CDT and GGT detect different populations of drinkers with regard to 
cardiovascular lipid risk factors (III, IV) 
 
The two cross-sectional studies (III, IV) were carried out to assess the relation between the 
markers of alcohol intake CDT and GGT and serum lipid profile. It was demonstrated that 
with increasing serum CDT concentrations, serum HDL cholesterol values were 
significantly higher and triglycerides lower in both men and women. This outcome may 
partly be caused by alcohol, since CDT, a potent biomarker of alcohol abuse (Sillanaukee 
1996, Allen et al. 1994), correlated positively with alcohol consumption. Numerous 
epidemiological studies have shown with consistency that moderate alcohol intake 
(variously defined but corresponding to one to four drinks per day) decreases risk of CHD 
(Doll 1997, Arriola et al. 2010). A part of the protection is thought to be mediated by the 
effects of alcohol on blood lipid metabolism, particularly increases in HDL cholesterol 
(Steinberg et al. 1991). Moreover, serum CDT was negatively associated with serum total 
cholesterol in women, but this effect disappeared after adjusting for age. This might be 
 56 
due to a decrease of CDT during menopause together with age-related increase of serum 
total cholesterol (Jousilahti et al. 1999). A negative association of CDT with triglycerides 
in the present study confirms findings of a previous study, which showed that triglyceride 
concentrations in diabetic individuals with high CDT values were low rather than high 
(Fagerberg et al. 1994). A mechanistic view behind this association is not clear. 
It is not known why chronic alcohol consumption elevates CDT levels in serum. 
One explanation might be that the activities of glycosyltransferases involved in transferrin 
carbohydrate side chain synthesis are diminished in the liver, at least in part, due to 
enzyme inactivation by acetaldehyde (Salvaggio et al. 1991). Alcohol also influences most 
metabolic pathways of the liver, and also several endocrine systems in the whole body.  
The mechanism behind the association of CDT and lipoprotein metabolism is also 
not clear at present. In our study BMI was inversely associated with CDT in both genders. 
However, even after adjusting for BMI, there was a strong independent association of 
CDT with HDL cholesterol and triglycerides. The baseline values of CDT have been 
shown to be fairly constant over time within the same individual, but there is some 
variation between individuals even without any alcohol consumption (Helander et al. 
1998). This could suggest that there is a yet unknown mechanism that may influence both 
(hepatic) CDT formation and lipoprotein metabolism. It is to be noted that the diagnostic 
value of CDT is not 100% sensitive and specific. For sensitivity and specificity of CDT 
and GGT as alcohol markers, see table 4 below. A number of confounding factors are 
known, e.g. pre-analytical issues, mutant transferrins, some metabolic diseases, body 
composition, arterial hypertension, drug treatment, and exposure to organic solvents 
(Delanghe and De Buyzere 2009).  
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TEST Sensitivity (%) Specificity (%) 
CDT 60-70 80-95 
GGT 40-60 80-90 
CDT+GGT 60-90 80-95 
 
Table 4. Generalized ranges of laboratory tests of alcohol dependence (Tavakoli et al. 
2011). 
 
In contrast to the CDT concentration, increasing serum GGT activity was 
associated with a more atherogenic lipid profile: higher serum total and LDL cholesterol 
concentration, and higher triglyceride concentration in both genders. It is possible that the 
association of GGT with total cholesterol and triglycerides reflects deranged liver lipid 
metabolism with possible fatty liver formation. This was not accounted for in the present 
studies, since the study subjects were not imaged for liver damage. Alcohol consumption 
is known to show a linear dose–response relationship with HDL cholesterol, but again this 
increase may be modulated by the degree of liver injury (Flegal and Cauley 1985). A 
positive correlation between GGT activity and HDL cholesterol has also been reported 
(Pintus and Mascia 1996). In the present study, there was actually a small decrease of 
HDL cholesterol values in both genders with increasing GGT, but in women this decrease 
lost its significance after adjustment for age, BMI and smoking. Our observations thus 
agree with earlier studies showing no positive correlation between GGT activity and HDL 
cholesterol (Fex et al. 1982, Sillanaukee et al. 1993b). Increases in serum GGT activity 
were associated with age and BMI in both genders, confirming earlier findings (Kanel et 
al. 1983, Holder et al. 1995). 
With regard to serum CDT concentration and GGT activity, an optimal lipid 
profile was observed in subjects who belonged to the highest quartile CDT group and 
simultaneously also to the lowest quartile GGT group, even after adjustment for age and 
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BMI. It is possible that CDT is an earlier stage or phase biomarker of alcohol 
consumption than GGT, and GGT might in fact reflect later on more toxic effects of 
ethanol on hepatic lipid metabolism, leading to hypercholesterolemia, decreased HDL 
cholesterol and hypertriglyceridemia (Sabesin 1981, Kanel et al. 1983). It has been shown 
previously that the development of alcoholic liver disease affects plasma lipid levels. HDL 
cholesterol concentration decreases and LDL cholesterol concentration increases in 
parallel with the degree of impairment of liver function in alcohol drinkers (Hannuksela et 
al. 2004). 
On the other hand, this hypothesis is not supported by the fact that the average 
self-reported alcohol consumption was 136 g per week for men and 42 g per week for 
women in the highest CDT quartile, and 138 g per week and 35 g per week in the highest 
GGT quartile, respectively. However, this alcohol consumption should be considered in 
the context that self-reporting of drinking is commonly unreliable and the official per 
capita mean consumption of absolute ethanol in Finland for inhabitants 15 years and older 
was 8.4 l per year at the time, corresponding to 162 g per week (Holder et al. 1995). Total 
alcohol consumption has increased since, being 10.5 l per year at 2007, corresponding to 
over 200 g per week (Stakes 2008). 
In conclusion, the present results indicate that serum CDT concentration is 
positively associated with alcohol consumption and serum HDL cholesterol, and inversely 
associated with serum triglycerides. On the other hand, alcohol consumption associated 
with liver induction and elevated GGT may have adverse effects on lipoprotein 
metabolism, including hypercholesterolemia and hypertriglyceridemia. CDT and GGT 
seem to detect different populations of subjects in regard to lipid metabolism. These 
observations may direct us to a better understanding of the effects of alcohol consumption 
on serum lipids as well as mechanisms behind favorable and detrimental effects of alcohol 
on vascular diseases.  
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7. SUMMARY AND CONCLUSIONS 
 
The present study investigated lipid and other atherosclerosis risk factor changes induced 
by HRT or ethanol consumption in subsamples representing the Finnish population. The 
major findings in these studies suggest that HRT and ethanol consumption affect the 
development of atherosclerosis partly depending on the genotype and phenotype of the 
individual examined. 
 
The major findings and conclusions are: 
 
1. Postmenopausal HRT with estradiol valerate alone, combined estradiol valerate–
levonorgestrel, and combined estradiol valerate–medroxyprogesterone is associated 
with less severe atherosclerotic lesions and diminished oxidation of LDL particles. 
2. The effect of HRT on progression of atherosclerosis in postmenopausal women may be 
determined in part by the genotype of estrogen receptor.  
3. CDT and GGT, when used as biomarkers for alcohol use, detect different populations 
of drinkers in regard to cardiovascular lipid risk factors. It appears that increased CDT 
concentration is associated with a favorable serum lipid profile, including higher HDL 
cholesterol and lower triglycerides. In contrast, increase in serum GGT activity appears 
to affect the lipid profile unfavorably. 
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Abstract
Background: In epidemiologic studies, the incidence of atherosclerosis rises soon after menopause in women, and hormone
replacement therapy (HRT) has proved to be useful in preventing onset of clinical manifestations of the disease. However, it is
not known how HRT affects sonographically determined atherosclerotic severity (AS) and number of atherosclerotic plaques
(NAP) in large arteries. Furthermore, it is not clear how HRT affects oxidation of low density lipoproteins (LDL), which
obviously has an important role in the pathogenesis of atherosclerosis. Objecties: The purpose of the study was to determine
whether HRT has a beneficial effect on sonographically determined AS and NAP in large arteries of 101 postmenopausal women
compared to 40 controls without HRT. We also studied the interaction of HRT and antibodies against oxidized LDL on AS and
NAP progression. Results: Estradiol valerate alone, combined estradiol valerate–levonorgestrel and combined estradiol valerate–
medroxyprogesterone acetate therapy are each associated with lower NAP and AS as compared to controls without HRT. In a
multiple regression model explaining NAP in the whole study population, the strongest predictors were HRT (P=0.0006) and
copper-oxidized LDL cholesterol autoantibodies (P=0.0491). Discussion: Our findings indicate that postmenopausal HRT is
associated with a lower total number of atherosclerotic plaques and less severe atherosclerotic lesions, as compared to controls
without HRT, and that this outcome may be associated with the effect of HRT on LDL cholesterol oxidation. © 2001 Elsevier
Science Ireland Ltd. All rights reserved.
Keywords: Hormone replacement therapy; Atherosclerosis; Sonography; LDL oxidation
www.elsevier.com/locate/atherosclerosis
1. Introduction
Atherosclerotic cardiovascular disease (CVD), causes
about one-half of the mortality and morbidity of hu-
mans in the western world. The incidence of CVD in
premenopausal women is about one-half of that in men
of similar age, but rises soon after menopause [1–3].
Most epidemiological studies suggest useful effects of
estrogens on the risk of CVD in postmenopausal
women [1,4]. Postmenopausal hormone replacement
therapy (HRT) ordinarily involves estrogen combined
with progestin. However, there is little data in humans
about the effects of combined estrogen–progestin ther-
apy on atherosclerosis, or on known risk factors, such
as oxidized LDL [5]. To our knowledge, the interaction
between long-term estrogen–progestin therapy and oxi-
* Corresponding author. Tel.: +358-3-2475554; fax: +358-3-
2475111.
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dized low-density lipoprotein (LDL) has not previously
been studied in terms of prediction of atherosclerosis.
Oxidized LDL is believed to play an important role
in the progression of atherosclerosis [6]. Oxidative mod-
ification of LDL is a prerequisite for rapid accumula-
tion of LDL in macrophages and for the formation of
foam cells. LDL isolated from atherosclerotic lesions,
but not from normal arteries, resembles oxidized LDL
in its physical, chemical, and immunological properties
[7]. Epitopes characteristic of oxidized LDL can be
found in atherosclerotic lesions by immunocytochemi-
cal techniques [8,9] and atherosclerotic lesions contain
immunoglobulins that recognize oxidized LDL [7,8]. In
addition, antioxidant therapy reduces atherogenesis in
animal models [10,11]. Antibodies against malondialde-
hyde or copper modified LDL, detected by radioim-
munoassay, have been reported to be predictive of the
progression of carotid atherosclerosis [12], coronary
artery disease (CAD) [13] and myocardial infarction
[14]. Furthermore, recent results from Heizer et al. [15]
and Raitakari et al. [16] indicate that antibodies against
copper-oxidized LDL are associated with impaired en-
dothelial function and early atherosclerotic changes
[13]. We hypothesized that there might be an oxidized
LDL by HRT interaction, which modulates atherogen-
esis. Therefore, the purpose of the present study was to
assess how long-term HRT affects atherosclerotic
changes in large arteries of postmenopausal women,
and whether there is an interaction between HRT and
oxidized LDL, compared to women who have never
used HRT.
2. Methods
2.1. Subjects
Women attending a private outpatient clinic in Tam-
pere for annual routine gynecological examinations
were invited to participate. For the cross-sectional base-
line study in 1993 [5], 141 non-smoking, non-diabetic
postmenopausal women aged 45–71 years were en-
rolled. They had no clinically evident cardiovascular
diseases or hypertension and were classified into four
groups based on the monthly use of HRT. The HRT-
EVP group (n=40) used estradiol valerate (EV) 2 mg
per day for 11 days followed by EV continued with
progestin (P, levonorgestrel 0.25 mg per day) for 10
days, the HRT-EVM group (n=21) used estradiol
valerate (EV) 2 mg per day for 11 days followed by EV
continued with progestin (M, medroxyprogesterone
acetate 10 mg per day) for 10 days, the HRT-EV group
(n=40) used EV alone, and the control group (n=40)
had never used HRT. In HRT-EVP, HRT-EVM and
HRT-EV groups there was a pause of therapy for 7
days after each 21-day cycle. Of these 141 women 91
(60 in HRT group, 31 controls) participated in 5-year
follow up study from 1993 to 1998. HRT, when used,
was started at the time of menopause for climacteric
symptoms. In the control group, the main reasons not
to use HRT were the absence of vasomotor and other
climacteric symptoms and dislike of HRT. The mean
duration of EVP and EVM was 9.33.2 years and of
EV treatment 9.94.2 years at the beginning of the
study. The mean time from menopause in the control
group was 11.94.1 years (mean 9.93.8 years, at
baseline). The mean ages in the HRT-EVP, HRT-
EVM, HRT-EV, and control groups were 59.6
4.7, 55.93.4, 61.05.0, and 61.65.5 years,
respectively (P=0.0002 over all groups in analysis of
variance, ANOVA). The mean body mass indexes were
(BMI, mean 25.33.2 kg/m2) similar in all studied
groups (P=0.8941 over all groups in ANOVA). In the
HRT-EV, HRT-EVP, and control groups 24, 4, and 6
women underwent hysterectomy, respectively, due to
benign conditions and 4, 2, and 2 women bilateral
salpingo-oophorectomy. At baseline, all women were
clinically healthy, and used no chronic medication.
Nutrient intake analyses were also performed, as de-
scribed elsewhere [5], and these analyses did not show
any marked differences between the study groups in the
amount of used saturated, monounsaturated, and
polyunsaturated fats, or dietary cholesterol. Sonogra-
phy and blood sampling were done in the University
Hospital of Tampere. The Ethics Committee of the
University Hospital of Tampere approved the study.
2.2. Blood samples
Blood samples for serum lipid and genotype analyses
were taken after the subjects had fasted overnight.
Sampling took place within 3 weeks after the sonogra-
phy and for HRT users during the third week of the
hormone regimen. After separation of serum by low-
speed centrifugation the sera were divided into aliquots
and stored at −70°C until analyzed.
2.3. Sonography
Sonography at baseline and follow-up were per-
formed with Toshiba Sonolayer V SSA 100 equipment,
as reported elsewhere [5]. Briefly, all the sonographies
were done blinded by one experienced sonographer and
radiologist (P.D.). During the examinations women
were lying in a supine position. Transverse and longitu-
dinal scans of extracranial carotid arteries were per-
formed bilaterally at four different segments of the
carotid: first, at the 10 mm segment of the common
carotid artery (CCA) just distal to the origin of carotid
bifurcation, second at a 10 mm segment in the area of
distal third of the CCA, third at the 10 mm segment
between origin of carotid bifurcation and the tip of the
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flow divider, which separates internal from external
carotid arteries, and fourth at a 10 mm segment of the
internal carotid artery cranial from flow divider. Only
fibrous and calcified atherosclerotic lesions were con-
sidered and were defined as plaques when distinct ar-
eas of mineralization or/and focal protrusion into the
lumen were identified. The thickness and length of
such plaques within the artery vessel wall were deter-
mined by transverse and longitudinal scans, respec-
tively, and the thickness of a plaque was determined
as the distance between the intimal– luminal interface
and the medial–adventitial interface. The intimal–me-
dial far-wall thickness equal to or more than 1.3 mm
at any segment in carotid arteries was defined as an
atherosclerotic plaque [17] and the total number of
plaques was calculated. All carotid artery examina-
tions were done with a 5.0 MHz convex transducer
probe.
Longitudinal sonographs of the abdominal aorta
were obtained at 1 cm intervals and transverse scans
at 2 cm intervals at the area of three aortic segments:
(1) supra-pancreatic; (2) pancreatic and infra-pancre-
atic; and (3) at the area of the aortic bifurcation. As
for carotid plaques, significant aortic plaques were
defined as an intimal–medial far-wall thickness equal
to or more than 3.0 mm [17]. All aortic examinations
were performed using a 3.75 MHz convex transducer
probe. The average duration for the whole examina-
tion varied from 25 to 30 min.
Predominantly fibrous plaque is moderately to
strongly echogenic and the degree of echogenity corre-
lates with the amount of collagen within the plaque
architecture [18]. Uniformly fibrous plaque is homoge-
nous in echogenity, but localized hypoechoic regions
may be seen when large focal deposits of lipid material
or thrombus are present within fibrous plaque [19,20].
Fibrofatty plaque is only faintly echogenic so may be
difficult to identify sonografically. It contains a large
amount of lipid material. The properties of fibrofatty
plaque are very similar to those of blood and thus
difficult to decipher. In our study, predominantly
fibrous plaques and uniformly fibrous plaques were
identified. Calcified plaque shows bright reflections
with acoustic shadowing. Tiny areas of calcification on
the order of 1 mm in diameter are detected within
plaques. Acoustic shadowing from large calcified de-
posits are troublesome to see on ultrasound [18].
The atherosclerotic severity sum (AS) was con-
structed by dividing the atherosclerotic changes of ab-
dominal aorta, iliac, and carotid arteries into three
severity classes: 1=slight, 2=moderate, and 3=
severe, and calculating the sum, i.e. AS. Total number
of atherosclerotic plaques (NAP) was calculated ac-
cording to the criteria given for plaques in Section 2.
The reproducibility of our sonographic protocol for
significant aortic and carotid plaques was also exam-
ined: 1 month after the first assessment 20 randomly
selected subjects were invited to a repeated examina-
tion. The repeatability of the number of plaques (num-
ber of plaques initial by repeated sonography) between
the first and second examination was 90% for the
carotid artery segment areas and 100% for the aortic
segments.
2.4. Enzyme-linked immunosorbent assay for antibodies
against oxidized LDL
Autoantibodies against oxidized LDL were deter-
mined as described earlier [13]. In short, antigens for
this assay included: (A) native LDL prepared from the
pooled plasma of ten donors and protected against
oxidation by 0.27 mmol/l EDTA and 20 mol/l buty-
lated hydroxytoluene (BHT) in phosphate buffered sa-
line (PBS); and (B) oxidized LDL obtained after 24-h
oxidation of the native LDL with 2 mol/l CuSO4.
For enzyme-linked immunosorbent assay, half of the
wells on a polystyrene plate (Nunc, Roskilde, Den-
mark) were coated with 50 l of native and the other
half with 50 l copper-oxidized LDL antigen (both at
a concentration of 5 g/ml) in PBS for 16 h at 4°C.
After removal of the unbound antigen and washing of
the wells, the remaining non-specific binding sites were
saturated using 2% human serum albumin in PBS and
20 mol/l BHT for 2 h at 4°C. After washing, 50 l of
the serum samples, diluted 1:20, were added to wells
coated with native LDL and oxidized LDL and incu-
bated overnight at 4°C. After incubation the wells
were aspirated and washed six times before an IgG-
peroxidase conjugated rabbit anti-human monoclonal
antibody (Organon, USA No. 55220 Cappel), diluted
1:4000 (v/v) in buffer (0.27 mmol/l PBS, 20 mol/l
EDTA, 1% BHT, 0.05% Tween HSA), was added to
each well for 4 h at 4°C. After incubation and wash-
ing, 50 l of freshly made substrate (0.4 mg/ml o-
phenylenediamine (Sigma) and 0.045% H2O2 in 100
mmol/l acetate buffer, pH 5.0) was added and incu-
bated exactly 5 min at room temperature. The enzyme
reaction was terminated by adding 50 l of 2 M
H2SO4. The optical density (OD) was measured at 492
nm using a microplate reader (Multiskan MCC/340,
Labsystems GmbH, Munich, FRG). All measurements
were blinded and done on coded serum samples. The
results were expressed as the mean OD values from
duplicate determinations, and autoantibody titer
against oxidized LDL was calculated by subtracting
the binding of antibodies to native LDL from that to
copper-oxidized LDL. This approach reduces the pos-
sibility of getting false positive values due to cross-re-
activity with both LDL epitopes. The intra-assay
coefficient of variation was for the antibodies against
oxidized LDL 8.5%.
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2.5. Other laboratory analyses
For the cross-sectional study the concentrations of
serum lipids and apolipoproteins were measured. Serum
total cholesterol and triglycerides were determined by a
commercial method (Kodak Echtachem 700XR, East-
man Kodak Company, Clinical Products Division,
Rochester, and USA). Serum HDL cholesterol and its
sub-fractions (HDL2 and HDL3) were separated by a
dextran–sulfate–Mg precipitation procedure [21] and
the cholesterol content was analyzed with a Monarch
2000 Analyzer (Instrumentation Laboratory, Lexington,
USA), using the CHOD-PAP cholesterol reagent (Cat
No. 237574; Boehringer Mannheim, Germany) and a
primary cholesterol standard (Cat No. 530; Orion, Fin-
land). The LDL cholesterol content was calculated
according to the Friedewald formula [22]. Apolipo-
proteins (apo) A1 and B were determined on a Monarch
Analyzer by an immunoturbidimetric method [23] (Cat
No. 67265 and 67249, Orion Diagnostics, Finland). In
the 5-year follow-up study the lipid concentrations were
determined with Cobas Integra 700 analyzer with
reagents and calibrations recommended by the manufac-
turer (Hoffmann-La Roche Ltd., Basel, Switzerland).
2.6. Statistical analysis
Two-way analysis of covariance (ANCOVA) using
age, BMI, and total cholesterol as covariates, when
appropriate) was used to assess the interaction between
grouping factor, HRT groups and control group, in
selected variables of interest (=dependent variables) i.e.
atherosclerotic severity score (AS), total number of
atherosclerotic plaques (NAP), and serum lipids, and
apolipoproteins. Two- and one-way analysis of variance
(ANCOVA) was used to assess the statistical differences
between HRT groups and control group in lipid parame-
ters shown in Table 1, age and BMI were used as
covariates when appropriate. In Table 1 pairwise com-
parisons of group means were done by using analysis of
variance, age and body mass index as covariates, when
appropriate. Multiple regression was used in search for
the variables that predict the severity of atherosclerosis.
We also used repeated measure analysis of variance to
study the effect of time and HRT on atherosclerotic
severity in our study population. All calculations were
done with the Statistica for Windows version 5.1 (Stat-
soft Inc., Tulsa, Oklahoma, USA) software in PC. Data
are presented as meanSD unless otherwise stated. A
P-value less than 0.05 was considered statistically signifi-
cant.
3. Results
The mean baseline values and differences of serum
lipids and apolipoproteins between study groups are
presented in Table 1. It is important to notice that the
subjects in the HRT groups had already received HRT
for 10 years at the beginning of this study. The HRT-
EVM group had the lowest baseline LDL/HDL choles-
terol ratio (2.22 vs. 3.15 in controls, P=0.0018) and
seemed to have the most profitable serum lipid profile
(see Table 1).
During the 5-year follow-up (see Table 2), the concen-
tration of HDL cholesterol increased and LDL choles-
terol decreased significantly in HRT-EV, HRT-EVP and
control groups, and total cholesterol decreased signifi-
cantly in the HRT-EV group and controls, but not in the
HRT-EVP group. The triglycerides increased in HRT-
EVP group and controls but not in the HRT-EV group.
The HRT-EVM group was not included in the follow-up
study.
In a multiple regression model explaining NAP in the
whole study population, the strongest predictors were
HRT (P=0.0006) and copper-oxidized LDL cholesterol
autoantibodies (P=0.0491). Other atherosclerotic risk
factors did not reach statistical significance in the model,
although there were statistically significant differences in
serum lipids between the HRT groups in analysis of
variance (Table 1 and Fig. 1). The results and the
parameters included in the model are presented in Table
3. In addition, Ox-LDL antibody titer and NAP are
visualized in scatterplot (Fig. 2). When HRT was re-
moved from the model, the role of oxidized LDL became
even stronger (P=0.0306 for HRT, P=0.0128 for the
whole model, data not shown), as the other parameters
remained insignificant. In a similar multiple regression
model explaining AS in the whole study population, the
strongest predictors were HRT (P=0.0024) and HDL
cholesterol (P=0.0024 for HRT, P=0.0412 for HDL,
R2=14% and P=0.0228 for the whole model, data not
shown). Likewise, when HRT was excluded from the
model, no significant parameters remained (P=0.25 for
the whole model, data not shown). In otherwise similar
regression models performed within different study
groups, HDL cholesterol explained AS and NAP in the
control group, but not in HRT groups (data not shown).
The effect of HRT on atherosclerosis was also seen in
repeated measures analysis of variance performed on the
5-year follow-up study population (n=91). We used the
AS of aorta and carotid artery as repeated measure, HRT
and control group as independent factor, and age and
body mass index as covariates. The HRT group and time
had no interaction (P=0.1389), and P-values for the
main effects of time and HRT group were 0.0000 and
0.0036, respectively. The result is presented in Fig. 1. The
AS after follow-up was significantly higher in HRT-EV
(n=34), HRT-EVP (n=26) and control (n=31) groups,
compared to baseline (data not shown).
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Table 1
Background characteristics in postmenopausal women without or with hormone replacement therapy (HRT)a
HRT-EVM HRT-EV SignificanceHRT-GROUP C vs. EVPControls C vs. EVM C vs. EVHRT-EVP
n=40 n=21 n=40 P-value P-valuen=40 P-valueVariable and P-value
unit
61.6 (5.5) 59.6 (4.7) 55.9 (3.4) 61.0 (5.0) 0.0002 0.0821 0.0001 0.6255Age, year
25.4 (3.0) 24.6 (3.7) 25.4 (2.9) 0.894125.4 (3.3) 0.9606Body mass 0.3914 0.9417
index, kg/m2
47.5 (19)Hypercholestero 27.5 (11) 23.8 (5) 47.5 (19) 0.2280 0.0685 0.0714 1.0000
lemia,% (n)
Triglycerides, 0.79 (0.21)1.25 (0.61) 1.13 (0.46) 1.47 (0.69) 0.0000 0.0000 0.4522 0.1391
mmol/l
6.70 (1.19) 5.92 (0.86) 5.91 (0.89) 6.56 (0.92) 0.0049Total 0.0013 0.0093 0.5543
cholesterol,
mmol/l
LDL 4.60 (1.14) 4.10 (0.91) 3.60 (0.92) 4.25 (0.85) 0.0372 0.0328 0.0011 0.1234
cholesterol,
mmol/l
0.84 (0.16) 0.82 (0.17) 0.98 (0.18) 0.0051Apolipoprotein 0.00940.96 (0.24) 0.0182 0.6874
B, g/l
1.54 (0.33) 1.47 (0.35) 1.79 (0.50) 1.65 (0.37) 0.0284HDL 0.3593 0.0250 0.1656
cholesterol,
mmol/l
HDL2 0.50 (0.22) 0.45 (0.30) 0.59 (0.24) 0.56 (0.27) 0.1581 0.3370 0.1881 0.3061
cholesterol,
mmol/l
1.34 (0.19) 1.57 (0.19) 1.56 (0.26)Apolipoprotein 0.00001.44 (0.19) 0.0325 0.0145 0.0163
A1, g/l
3.15 (1.08) 2.96 (1.04) 2.22 (1.01) 2.70 (0.82) 0.0329LDL/HDL 0.4273 0.0018 0.0369
cholesterol
ratio
Total number 3.88 (2.09) 2.65 (1.75) 2.10 (1.58) 2.18 (1.69) 0.0005 0.0163 0.0107 0.0001
of plaques
1.48 (0.91) 1.52 (1.03) 1.38 (0.98) 0.0227 0.0240 0.1922 0.0048Atherosclerotic 2.05 (1.06)
severity
2.61 (1.92) 2.19 (1.92) 2.08 (0.77) 0.3320 0.1952 0.9420 0.49082.20 (0.95)Oxidized LDL
antibodies
a Values are means (SD), unless stated otherwise (significant results are in bold). LDL, low density lipoprotein; HDL, high density
lipoprotein; C, controls; EV, estradiol valerate, 2.0 mg per day; P, levonorgestrel, 2.5 mg per day; M, medroxyprogesterone acetate.
Hypercholesterolemia= total cholesterol6.5 mmol/l. Significance is based on analysis of covariance, age and body mass index as covariates,
when appropriate.
Table 2
Changes in serum lipid profile during the follow-upa
Controls (n=40) HRT-EVP (n=40)Group HRT-EV (n=40)
1993 1998Variable and P-value1993 1993 1998 P-value1998 P-value
unit
0.79 (0.21) 1.08 (0.75) 0.0201 1.47 (0.69)1.25 (0.61) 1.52 (0.53)1.48 (0.67) 0.64020.0393Triglycerides,
mmol/l
Total 6.23 (0.95) 0.0043 5.92 (0.86) 5.79 (1.25) 0.5552 6.56 (0.92) 6.10 (0.84) 0.00026.70 (1.19)
cholesterol,
mmol/l
0.0000 4.10 (0.91)LDL 3.56 (1.04)4.60 (1.14) 0.0005 4.25 (0.85) 3.65 (0.83) 0.00003.89 (0.87)
cholesterol,
mmol/l
0.0023 1.47 (0.35) 1.74 (0.37) 0.00001.54 (0.33) 1.65 (0.37)HDL 1.76 (0.42) 0.04421.67 (0.41)
cholesterol,
mmol/l
a Values are means (SD), unless stated otherwise (significant results are in bold). LDL, low density lipoprotein; HDL, high density
lipoprotein; C, controls; EV, estradiol valerate, 2.0 mg per day; P, levonorgestrel, 2.5 mg per day. Significance is based on repeated measures
analysis of variance, age and body mass index as covariates.
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Fig. 1. Repeated measures analysis of variance. Atherosclerotic severity is estimated from aorta and carotid artery by sonography. There was no
interaction between the main effects (P=0.1389).
4. Discussion
In this conservative study design, we show that oxi-
dized LDL autoantibodies seem to predict NAP in
postmenopausal women, but do not seem to explain
AS. To increase our understanding of the effects of
HRT on atherosclerosis in postmenopausal women, we
tested the relationship of oxidized LDL autoantibodies
and three different HRTs in the occurrence of
atherosclerosis (as measured by AS and total NAP),
after considering the contribution of some other CVD
risk factors i.e. age, BMI and serum cholesterol. Fur-
ther, in this study all subjects were non-smokers, did
not have diabetes, had normal blood pressure, and were
otherwise clinically healthy. The time elapsed from
menopause was similar in HRT groups and controls. In
addition, the dietary analysis did not reveal any sub-
stantial differences in the use of saturated fat or dietary
cholesterol intake between the HRT and control
groups. Therefore, our findings are unlikely to be
caused by different dietary habits between the groups.
Since some other important factors that may differ
between HRT and control groups (i.e. socioeconomic
status, family history of CVD) were not accounted for,
one can say that these unknown factors may have
biased our results.
Previous studies have shown that postmenopausal
estrogen therapy reduces the risk of CVD [24–26]. The
positive effects of postmenopausal HRT on serum lipo-
proteins have been widely examined, although it is
estimated that lipoprotein changes explain only 25–
50% of the beneficial effect of estrogen [24]. Recently it
has been shown that estrogens also prevent atheroscle-
rosis by directly affecting the function and metabolism
of the arterial wall. For example, estrogens reduce the
accumulation of cholesterol in the arterial wall [27].
Other reported mechanisms are effects on prostaglandin
metabolism [28] and on blood flow [29]. Mendelshon
and Karas have written an in-depth review of the
protective effects of estrogen on the cardiovascular
system [30], in which they list systemic effects and direct
effects of estrogen on the cardiovascular system. To our
knowledge, estrogen has never been shown to slow
atherosclerosis progression in women in randomized
Table 3
Multiple regression model of risk factors predicting total number of
atherosclerotic plaques in postmenopausal women receiving hormone
replacement therapy and controlsa
P-valuebVariable
Hormone replacement therapy 0.0006 (0.0007)
0.0491 (0.0255)Copper-oxidized LDL autoantibodies
0.0568 (0.3609)HDL cholesterol
Age 0.1108 (0.0646)
Triglycerides 0.1309 (0.2362)
Total cholesterol 0.1333 (0.3873)
Total cholesterol — HDL cholesterol ratio 0.2671 (0.2087)
0.3846 (0.5383)Body mass index
0.3869 (0.1552)Dietary saturated fat intake
Dietary cholesterol intake 0.7732 (0.8051)
a Total model: R2=22%. P=0.00025 for the whole model.
b In parentheses are the P-values when total cholesterol, HDL
cholesterol and triglyceride concentration changes are included in the
model instead of baseline values; then R2=21% and P=0.00061 for
the whole model.
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Fig. 2. Scatterplot of oxidized LDL antibody titer on X-axis and number of atherosclerotic plaques on Y-axis.
clinical trials [31,32], despite numerous findings from
non-randomized experiments showing that post-
menopausal estrogen therapy has favorable effects on
serum lipoprotein concentrations and slows the devel-
opment of atherosclerotic diseases. Furthermore, in
some studies no beneficial effect [33], and even an
increase in the incidence of cardiovascular disease [34],
have been reported to be associated with HRT. In the
present work we show that both time and HRT have an
independent effect on AS.
HRT usually combines estrogen with progestin.
However, there is little information on the effects of
estrogen–progestin therapy on atherosclerosis. It is
known that some progestins have unfavorable effects
on lipid metabolism, while some do not [35–37]. Our
study is in line with the study of Punnonen et al. [5],
who have demonstrated that combined estrogen–
progestin replacement therapy prevents the progression
of atherosclerosis in large arteries in postmenopausal
women.
In recent years, autoantibodies against oxLDL have
been widely studied and have been found to predict the
progression of carotid atherosclerosis [12] and myocar-
dial infarction [14,38]. There is evidence that estrogens
inhibit oxidative modification of LDL [39], which is
believed to be one of the early events involved in the
progression of atherosclerosis. It has been suggested
that the antioxidative effect of estradiol may be anti-
atherogenic by reducing the likelihood of oxidative
modification of LDL, and thus preventing foam-cell
formation and lipid accumulation within blood vessel
walls [40,41]. In the study of Heikkinen et al. [42], a
1-year combined estrogen–progestogen treatment was
not effective in changing the oxidized LDL autoanti-
body titer, regardless of the beneficial effects on the
serum lipid parameters. In the present study, we show
that the level of oxidized LDL autoantibodies seems to
predict NAP in postmenopausal women. It is important
to note that the subjects had already used HRT for
almost 10 years at the beginning of the study. This may
have resulted in the somewhat unexpected finding that
oxidized LDL autoantibodies did not predict AS. One
could hypothesize that the progression of early
atherosclerotic changes to more advanced forms of
atherosclerotic lesions has been slowed by HRT.
In conclusion, our finding indicates that both estra-
diol valerate alone, combined estradiol valerate–
levonorergestrel, and combined estradiol
valerate–medroxyprogesterone acetate therapy are as-
sociated with lower total number of atherosclerotic
plaques and less severe atherosclerotic lesions, as com-
pared to controls without HRT, and that this outcome
may be associated with the effect of HRT on LDL
oxidation.
Acknowledgements
This study was supported by grants from the Finnish
Foundation of Cardiovascular Research, the Elli and
Elvi Oksanen Fund of the Pirkanmaa Fund under the
auspices of Finnish Cultural Foundation and the Medi-
cal Research Fund of the Tampere University Hospital.
The authors thank Nina Peltonen for her skillful tech-
nical assistance.
References
[1] Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson
BE. Menopausal oestrogen therapy and protection from death
from ischaemic heart disease. Lancet 1981;1:858–60.
T.A. Koiu et al. / Atherosclerosis 157 (2001) 471–479478
[2] Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK,
Szklo M. Association of hormone-replacement therapy with
various cardiovascular risk factors in postmenopausal women.
The atherosclerosis risk in communities study investigators. N
Engl J Med 1993;328:1069–75 see comments.
[3] Chae CU, Ridker PM, Manson JE. Postmenopausal hormone
replacement therapy and cardiovascular disease. Thromb
Haemost 1997;78:770–80.
[4] Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal
estrogen therapy and cardiovascular disease. Ten-year follow-up
from the nurses’ health study. N Engl J Med 1991;325:756–62
see comments.
[5] Punnonen RH, Jokela HA, Dastidar PS, Nevala M, Laippala
PJ. Combined oestrogen–progestin replacement therapy pre-
vents atherosclerosis in postmenopausal women. Maturitas
1995;21:179–87.
[6] Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized
low-density lipoproteins in the pathogenesis of atherosclerosis.
Annu Rev Med 1992;43:219–25.
[7] Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D,
Witztum JL. Rabbit and human atherosclerotic lesions contain
IgG that recognizes epitopes of oxidized LDL. Arterioscler
Thromb 1994;14:32–40.
[8] Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density
lipoprotein undergoes oxidative modification in vivo. Proc Natl
Acad Sci USA 1989;86:1372–6.
[9] Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for
the presence of oxidatively modified low density lipoprotein in
atherosclerotic lesions of rabbit and man. J Clin Invest
1989;84:1086–95.
[10] Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of
probucol unrelated to its hypocholesterolemic effect: evidence
that antioxidants in vivo can selectively inhibit low density
lipoprotein degradation in macrophage-rich fatty streaks and
slow the progression of atherosclerosis in the Watanabe heritable
hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725–9.
[11] Kita T, Nagano Y, Yokode M, et al. Probucol prevents the
progression of atherosclerosis in Watanabe heritable hyperlipi-
demic rabbit, an animal model for familial hypercholesterolemia.
Proc Natl Acad Sci USA 1987;84:5928–31.
[12] Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody
against oxidised LDL and progression of carotid atherosclerosis.
Lancet 1992;339:883–7 see comments.
[13] Lehtimaki T, Lehtinen S, Solakivi T, et al. Autoantibodies
against oxidized low density lipoprotein in patients with angio-
graphically verified coronary artery disease. Arterioscler Thromb
Vasc Biol 1999;19:23–7.
[14] Puurunen M, Manttari M, Manninen V, et al. Antibody against
oxidized low-density lipoprotein predicting myocardial infarc-
tion. Arch Intern Med 1994;154:2605–9 published erratum ap-
pears in Arch. Intern. Med. 1995 April 24;155(8):817.
[15] Heitzer T, Yla-Herttuala S, Luoma J, et al. Cigarette smoking
potentiates endothelial dysfunction of forearm resistance vessels
in patients with hypercholesterolemia. Role of oxidized LDL.
Circulation 1996;93:1346–53.
[16] Raitakari OT, Pitkanen OP, Lehtimaki T, et al. In vivo low
density lipoprotein oxidation relates to coronary reactivity in
young men. J Am Coll Cardiol 1997;30:97–102.
[17] Furberg CD, Byington RP, Borhani NA. Multicenter isradipine
diuretic atherosclerosis study (MIDAS). Design features. The
Midas Research Group. Am J Med 1989;86:37–9.
[18] Wolverson MK, Bashiti HM, Peterson GJ. Ultrasonic tissue
characterization of atheromatous plaques using a high resolution
real time scanner. Ultrasound Med Biol 1983;9:599–609.
[19] Lusby RJ, Ferrell LD, Ehrenfeld WK, Stoney RJ, Wylie EJ.
Carotid plaque hemorrhage. Its role in production of cerebral
ischemia. Arch Surg 1982;117:1479–88.
[20] Imparato AM, Riles TS, Gorstein F. The carotid bifurcation
plaque: pathologic findings associated with cerebral ischemia.
Stroke 1979;10:238–45.
[21] Nquven T, Warnig R. Improved method for separation of total
HDL cholesterol and subclasses. Clin Chem 1989;35:1086.
[22] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem
1972;18:499–502.
[23] Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric
determination of apolipoproteins A-1 and B in serum. Scand J
Clin Lab Invest 1987;47:739–44.
[24] Barrett-Connor E, Bush TL. Estrogen and coronary heart dis-
ease in women. J Am Med Assoc 1991;265:1861–7 see
comments.
[25] Kannel WB, Hjortland MC, McNamara PM, Gordon T.
Menopause and risk of cardiovascular disease: the Framingham
study. Ann Intern Med 1976;85:447–52.
[26] Stampfer MJ, Colditz GA. Estrogen replacement therapy and
coronary heart disease: a quantitative assessment of the epidemi-
ologic evidence. Prev Med 1991;20:47–63.
[27] Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen
monotherapy and combined estrogen–progestogen replacement
therapy attenuate aortic accumulation of cholesterol in ovariec-
tomized cholesterol-fed rabbits. J Clin Invest 1991;87:1274–9.
[28] Steinleitner A, Stanczyk FZ, Levin JH, et al. Decreased in vitro
production of 6-keto-prostaglandin F1 alpha by uterine arteries
from postmenopausal women. Am J Obstet Gynecol
1989;161:1677–81.
[29] Lau TK, Wan D, Yim SF, Sanderson JE, Haines CJ. Prospec-
tive, randomized, controlled study of the effect of hormone
replacement therapy on peripheral blood flow velocity in post-
menopausal women. Fertil Steril 1998;70:284–8.
[30] Mendelsohn ME, Karas RH. The protective effects of estrogen
on the cardiovascular system. N Engl J Med 1999;340:1801–11.
[31] Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B,
Vittinghoff E. Randomized trial of estrogen plus progestin for
secondary prevention of coronary heart disease in post-
menopausal women. Heart and estrogen/progestin replacement
study (HERS) research group. J Am Med Assoc 1998;280:605–
13 see comments.
[32] Herrington DM. The HERS trial results: paradigms lost? Heart
and estrogen/progestin replacement study. Ann Intern Med
1999;131:463–6.
[33] Rosenberg L, Armstrong B, Jick H. Myocardial infarction and
estrogen therapy in post-menopausal women. N Engl J Med
1976;294:1256–9.
[34] Gordon T, Kannel WB, Hjortland MC, McNamara PM.
Menopause and coronary heart disease. The Framingham study.
Ann Intern Med 1978;89:157–61.
[35] Hirvonen E, Malkonen M, Manninen V. Effects of different
progestogens on lipoproteins during postmenopausal replace-
ment therapy. N Engl J Med 1981;304:560–3.
[36] Barnes RB, Roy S, Lobo RA. Comparison of lipid and andro-
gen levels after conjugated estrogen or depo-medroxyproges-
terone acetate treatment in postmenopausal women. Obstet
Gynecol 1985;66:216–9.
[37] Sonnendecker EW, Polakow ES, Benade AJ, Simchowitz E.
Serum lipoprotein effects of conjugated estrogen and a sequen-
tial conjugated estrogen–medrogestone regimen in hysterec-
tomized postmenopausal women. Am J Obstet Gynecol
1989;160:1128–34.
[38] Bui MN, Sack MN, Moutsatsos G, et al. Autoantibody titers to
oxidized low-density lipoprotein in patients with coronary
atherosclerosis. Am Heart J 1996;131:663–7.
T.A. Koiu et al. / Atherosclerosis 157 (2001) 471–479 479
[39] Maziere C, Auclair M, Ronveaux MF, Salmon S, Santus R,
Maziere JC. Estrogens inhibit copper and cell-mediated modifica-
tion of low density lipoprotein. Atherosclerosis 1991;89:175–82.
[40] Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural
antioxidants of membrane phospholipid peroxidation. FEBS Lett
1987;210:37–9.
[41] Yla-Herttuala S, Luoma J, Kallionpaa H, Laukkanen M, Lehto-
lainen P, Viita H. Pathogenesis of atherosclerosis. Maturitas
1996;23:S47–9 Suppl.
[42] Heikkinen AM, Niskanen L, Yla-Herttuala S, et al. Post-
menopausal hormone replacement therapy and autoantibodies
against oxidized LDL. Maturitas 1998;29:155–61.
.
The effect of hormone replacement therapy on atherosclerotic
severity in relation to ESR1 genotype in postmenopausal
women
Tommi A. Koivu a,b,1, Yue-Mei Fan a,b,1, Kari M. Mattila a,b, Prasun Dastidar c,
Hannu Jokela a, Seppo T. Nikkari d, Tarja Kunnas d, Reijo Punnonen e,
Terho Lehtima¨ki a,b,*
a Laboratory of Atherosclerosis Genetics, Center for Laboratory Medicine, University Hospital of Tampere, P.O. Box 2000, 33521,
Tampere, Finland
b Tampere University Medical School, Department of Clinical Chemistry, University Hospital of Tampere, Tampere, Finland
c Department of Diagnostic Radiology, University Hospital of Tampere, Tampere, Finland
d Department of Medical Biochemistry, Tampere University Medical School, Tampere, Finland
e Department of Obstetrics and Gynecology, University Hospital of Tampere, Tampere, Finland
Received 9 February 2001; received in revised form 21 May 2002; accepted 15 July 2002
Abstract
Objective: The atheroprotective action of estrogen is mediated by estrogen receptors (ESR ) 1 and 2 , expressed in
atherosclerotic lesions. The effects of hormone replacement therapy (HRT) and ESR1 PvuII genotypes on
atherosclerosis have not previously been studied prospectively in postmenopausal women. Methods: We investigated
the effect of HRT on the progression of atherosclerosis in a 5-year follow-up study of 88 postmenopausal women aged
45/71 years at baseline allocated into three groups based on the use of HRT. The HRT-EVP group (n/ 26) used
sequential estradiol valerate (EV) plus progestin (P), the HRT-EV group EV alone (n/ 32), and a control group (n/
30) was without HRT. The atherosclerosis severity score (AS) of the abdominal aorta and carotid arteries were
determined by sonography and the ESR1 PvuII genotypes (P/P, P/p and p/p) by PCR. Results: HRT, time and ESR1
PvuII genotype had a statistically significant or borderline significant main effect on AS during 5-year follow-up (P/
0.004, PB/0.001 and P/0.090, respectively), when analyzed by repeated measures analysis of variance. There was a
significant genotype-by-treatment (HRT-EVP and control groups) interaction for AS (P/0.034). In response to HRT-
EVP, subjects with P/P, compared with those with P/p and p/p genotypes, had a less increase in AS (1.619/1.14 vs.
1.719/1.27 vs. 2.439/1.27). Baseline AS as covariate in similar model does not change the significant interaction effect
between HRT-EVP and control groups (P/0.036). But this effect was not found between HRT-EV and control
groups. Conclusions: Our results suggest that the effect of HRT-EVP in postmenopausal women on progression of AS
may be determined in part by the genotype of ESR1 PvuII.
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1. Introduction
Atherosclerotic diseases cause about one-half of
the mortality and morbidity of humans in the
western world [1]. Physiological disruption of
atheromatous lesions often underlies acute coron-
ary syndromes such as myocardial infarction,
angina, or sudden death due to coronary artery
occlusion [2]. Numerous findings from non-rando-
mised experiments show that postmenopausal
estrogen therapy has favorable effects on serum
lipoprotein concentrations and slows the develop-
ment of atherosclerotic disease [3,4]. However,
estrogens have not been shown to slow athero-
sclerotic progression in women in randomised
clinical trials [5,6]. It is estimated that estrogen-
induced alterations in serum lipids account for
only approximately one third of the possible
clinical benefits of estrogens, suggesting that also
the direct actions of estrogens on blood vessels
contribute substantially to their atheroprotective
effects [3,4]. In these previous studies, the possible
inherited genotypic effects on estrogen function
are not considered. Therefore, it would be inter-
esting to find out if there is a genetic subgroup of
women, which would benefit more from estrogens
than other.
The atheroprotective action of estrogens may be
mediated by estrogen receptors (ESR ) 1 and 2 ,
expressed in atherosclerotic lesions [3]. ESR1
activates specific target genes in vascular smooth
muscle [7], inhibits smooth muscle cell migration
[8,9] and accelerates endothelial cell growth in
vitro [10] and vivo [11,12]. In addition, fewer
ESR1 are found in premenopausal women with
atherosclerotic coronary arteries than in those
with normal arteries [13]. Therefore, it is possible
that the effects of estrogens on vascular cells,
mediated by ESR1 , differ due to the ESR1 variant
forms that have different transcriptional effects
than the ‘wild-type’ receptor [14,15]. ESR1 has a
common two-allele polymorphism for PvuII re-
striction enzyme, leading to genotypes P/P, P/p,
and p/p [16]. The PvuII polymorphism is caused
by a T-to-C transition in intron 1 and is located
approximately 0.4 kb upstream of exon 2 [16].
Hormone replacement therapy (HRT) may
protect against the development of atherosclerosis
and several epidemiological studies suggest that
estrogens are beneficial with respect to the risk of
cardiovascular diseases in postmenopausal women
[17/23]. However, the effect of HRT on the
development of atherosclerosis in people with
different ESR1 PvuII genotypes has not previously
been studied prospectively in postmenopausal
women. Postmenopausal HRT usually involves
estrogens with or without progestin. To our
knowledge, the interaction between HRT and
genetic factors has not been studied previously in
relation to prediction of atherosclerosis progres-
sion.
2. Materials and methods
2.1. Subjects
Women attending the private outpatient clinic
in Tampere for annual routine gynecological
examinations were invited to participate. For the
cross-sectional baseline study in 1993 [21], 120
non-smoking, non-diabetic postmenopausal wo-
men aged 45/71 years were enrolled. Eighty-eight
of 120 women participated in this 5-year follow-up
study from 1993 to 1998. They had no clinically
evident cardiovascular diseases or hypertension
and were classified into three groups based on the
use of HRT. The HRT-EVP group (n/ 26) used
estradiol valerate (EV) 2 mg/day for 11 days
followed by EV continued with progestin (P,
levonorgestrel 0.25 mg/day) for 10 days, the
HRT-EV group (n/ 32) used EV alone, and the
control group (n/ 30) had never used HRT. In
HRT-EVP and HRT-EV groups there was a pause
of therapy for 7 days after each 21-day cycle.
HRT, when used, was started at the time of
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menopause for climacteric symptoms. In the con-
trol group the main reason not to use HRT was
the absence of vasomotor and other climacteric
symptoms and dislike of HRT. The mean duration
of EVP was 9.39/3.2 years and of EV treatment
9.99/4.2 years. The mean time from menopause in
the control group was 11.99/4.1 years (mean 9.99/
3.8 years, at baseline). The mean ages in the HRT-
EVP, HRT-EV, and control groups were 59.79/
5.5, 60.49/4.8, and 61.59/5.8 years, respectively
(P/0.4409 over all groups in analysis of variance,
ANOVA). The mean body mass index was (BMI,
mean 25.79/3.0 kg/m2) similar in all studied
groups (P/0.9531 over all groups in ANOVA).
At baseline, all women were clinically healthy, and
used no chronic medication. Nutrient intake
analyzes were also performed as, described else-
where [21], and these analyzes did not show any
marked differences between the study groups in
the amount of used saturated, monounsaturated,
and polyunsaturated fats, or dietary cholesterol.
Sonography and blood sampling were done in the
University Hospital of Tampere. The Ethics Com-
mittee of the University Hospital of Tampere
approved the study. The investigation conforms
with the principles outlined in the Declaration of
Helsinki [24].
2.2. Blood samples
Blood samples for serum lipid analysis were
taken after the subjects had fasted overnight at
baseline and after 5-year follow-up. Genotype
analysis was performed using blood at baseline.
Sampling took place within 3 weeks after the
sonography and for HRT users during the third
week of the hormone regimen. After separation of
serum by low-speed centrifugation the serums was
divided into aliquots and stored at /70 8C until
analyzed.
2.3. Sonography
Sonography at baseline and follow-up were
performed with Toshiba Sonolayer V SSA 100
equipment, as reported elsewhere [21]. Briefly, all
the sonographies were done blinded by one
experienced sonographer and radiologist. During
the examinations women were lying in a supine
position. Transverse and longitudinal scans of
extracranial carotid arteries were performed bilat-
erally at four different segments of the carotid:
first, at the 10 mm segment of the common carotid
artery (CCA) just distal to the origin of carotid
bifurcation, second at a 10 mm segment in the area
of distal third of the CCA, third at the 10 mm
segment between origin of carotid bifurcation and
the tip of the flow divider, which separates internal
from external carotid arteries, and fourth at a 10
mm segment of the internal carotid artery cranial
from flow divider. Only fibrous and calcified
atherosclerotic lesions were considered and were
defined as plaques when distinct areas of miner-
alization or/and focal protrusion into the lumen
were identified. The thickness and length of such
plaques within the artery vessel wall were deter-
mined by transverse and longitudinal scans, re-
spectively, and the thickness of a plaque was
determined as the distance between the intimal/
luminal interface and the medial/adventitial inter-
face. The intimal-media far-wall thickness equal to
or more than 1.3 mm at any segment in carotid
arteries was defined as an atherosclerotic plaque
[25]. All carotid artery examinations were done
with a 5.0 MHz convex transducer probe.
Longitudinal sonographs of the abdominal
aorta were obtained at 1-cm intervals and trans-
verse scans at 2-cm intervals at the area of three
aortic segments: (1) supra-pancreatic, (2) pancrea-
tic and infra-pancreatic, (3) and at the area of the
aortic bifurcation. As for carotid plaques, signifi-
cant aortic plaques were defined as an intima-
media far-wall thickness equal to or more than 3.0
mm [25]. All aortic examinations were performed
using a 3.75 MHz convex transducer probe. The
average duration for whole examination varied
from 25 to 30 min.
The atherosclerotic severity score (AS) was
constructed by dividing the atherosclerotic
changes of abdominal aorta and carotid arteries
into three severity classes: 1*/slight, 2*/moderate,
and 3*/severe, and calculating the sum, i.e. AS.
The reproducibility of our sonographic protocol
for significant aortic and carotid plaques was also
examined: 1 month after the first assessment 20
randomly selected subjects were invited to a
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repeated examination. The repeatability of the
number of plaques (number of plaques initial by
repeated sonography) between the first and second
examination was 90% for the carotid artery
segment areas and 100% for the aortic segments.
2.4. DNA extraction and ESR1 genotyping
DNA was isolated from white blood cells using
commercial kit (Qiagen Inc, CA). A region of the
ESR1 gene containing a part of intron one and
exon two was amplified using primary and sec-
ondary (nested) primers designed from those
reported by Yaich et al. [16]. After digestion of
the PCR product with PvuII restriction endonu-
clease, fragments were separated using agarose gel
(1.0%) electrophoresis. Capital (P, mutated) and
small (p, wild type) letters denoted the absence and
presence of the restriction sites, respectively.
2.5. Other laboratory analyzes
For the cross-sectional study the concentrations
of serum lipids and apolipoproteins (apo) were
measured. Serum total cholesterol and triglycer-
ides were determined by a commercial method
(Kodak Echtachem 700XR, Eastman Kodak
Company, Clinical Products Division, Rochester,
USA). Serum HDL cholesterol were separated by
a dextran/sulfate/Mg precipitation procedure
[26] and the cholesterol content was analyzed
with a Monarch 2000 Analyzer (Instrumentation
Laboratory, Lexington, USA), using the CHOD-
PAP cholesterol reagent (Cat No. 237574; Boeh-
ringer Mannheim, Germany) and a primary cho-
lesterol standard (Cat No. 530; Orion, Finland).
The LDL cholesterol content was calculated
according to the Friedewald formula [27]. Apo
A1 and B were determined on a Monarch Analy-
zer by an immunoturbidimetric method [28] (Cat
No. 67265 and 67249, Orion Diagnostics, Fin-
land). In the 5-year follow-up study the lipid
concentrations were determined with Cobas Inte-
gra 700 analyzer with reagents and calibrations
recommended by the manufacturer (Hoffmann-La
Roche Ltd, Basel, Switzerland).
2.6. Statistical analysis
Two-way ANOVA was used to assess the
interaction between ESR1 PvuII genotype groups
and treatment groups. One-way ANOVA was used
to assess the statistical differences between HRT
groups and control group and among ESR1 PvuII
genotypes in lipid parameters. We also used
repeated measures analysis of variance (RA-
NOVA) to study the effect of time, ESR1 PvuII
genotype and HRT on AS in our study popula-
tion. All calculations were done with the Statistica
for Windows version 5.1 (Statsoft Inc., Tulsa,
Oklahoma, USA) software in PC. Data are pre-
sented as mean9/SD unless otherwise stated. A P -
value less than 0.05 was considered statistically
significant.
3. Results
Table 1 presents the baseline characteristics of
subjects according to ESR1 PvuII genotype. The
mean age, BMI, total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides, apo A1 and
apo B were not significantly different among the
genotypes. Subjects with the P/P genotype had a
higher AS (1.939/0.92) as compared with P/p
(1.249/0.85) and p/p (1.439/0.84) genotypes (P/
0.012).
Table 2 shows the baseline and final values and
change of lipid levels and AS in postmenopausal
women among treatment groups. The changes of
total cholesterol, triglycerides, LDL cholesterol,
apo A1 and apo B during 5-year follow-up were
not significantly different among three treatment
groups. Subjects in HRT-EVP group had higher
changes of HDL cholesterol and less progression
of AS compared with subjects in control group,
although this effect was borderline significant
(P/0.071 and P/0.084, respectively). Subjects
in HRT-EV group had less progression of AS
compared with subjects in control group (PB/
0.05).
Table 3 shows the baseline and final values and
change of lipid levels and AS in three treatment
groups according to genotype. There was a border-
line significant genotype-by-treatment interaction
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for AS (P/0.078, P/0.084 when AS baseline as
covariate). There was a significant genotype-by-
treatment (HRT-EVP and control groups) inter-
action for AS (P/0.034). In response to HRT-
EVP, subjects with P/P, compared with those with
P/p and p/p genotypes, had a less increase in AS
(1.619/1.14 vs. 1.719/1.27 vs. 2.439/1.27). When
AS at baseline as covariate in above similar model,
the significant genotype-by-treatment interaction
for changes of AS between HRT-EVP and control
groups was still remained (P/0.036). But this
effect was not found between HRT-EV and
control groups.
The effect of HRT and ESR1 PvuII genotype on
AS was also seen in RANOVA. We used AS as
repeated measure, treatment groups, and ESR1
PvuII genotype as independent factors, and age as
covariate. HRT treatment, time, and ESR1 PvuII
genotype had a statistically significant or border-
line significant main effect on progression of AS
during 5-year follow-up (P/0.004, PB/0.001, and
P/0.090, respectively). The result is presented in
Fig. 1.
4. Discussion
The present study shows that both long-term
HRT and ESR1 PvuII genotype have effects on
AS in postmenopausal women during 5-year
follow-up. All subjects in this study were non-
smokers, did not have diabetes, had normal blood
pressure, and were also otherwise clinically
healthy. The dietary analysis did not reveal any
substantial differences in the use of saturated fat or
dietary cholesterol between the HRT groups [21].
Therefore, our findings are unlikely to be caused
by differences in background characteristics be-
tween the HRT and control groups [21]. Since,
some other factors that may differ between HRT
users and non-users (i.e. socioeconomic status,
family history) were not accounted, one can say
that these unknown factors may have biased our
results.
Estrogen has never been shown to slow athero-
sclerosis progression in women in randomized
clinical trials [5,6], despite numerous findings
from non-randomized experiments showing that
postmenopausal estrogen therapy has favorable
effects on the serum lipoprotein profile and slows
the development of atherosclerotic diseases
[19,20,23,29]. Our findings might at least partly
explain these contradictory results. In these pre-
vious studies, the possible genotypic effects on
HRT response are not considered. Therefore, it
would be interesting to perform a reanalysis of
previous negative trials [5,6] to find out if there is a
genetic subgroup, which would benefit more from
HRT than other groups. Although ESR1 is
expressed in the atherosclerotic plaque [13], no
previous study has investigated the association of
ESR1 gene variation with AS. It is possible that
the transcriptional effects of ESR1 variant forms
differ from the ‘wild-type’ receptor and might thus
Table 1
Baseline characteristics of 88 postmenopausal women according to ESR1 Pvu II genotypes
Variable and unit P/P (n/ 14) P/p (n/ 46) p/p (n/ 28) P -value
Age, years 59.49/5.39 60.79/5.08 61.09/5.84 0.670
Body mass index (kg/m2) 27.09/3.11 25.39/3.05 25.89/2.88 0.218
Total cholesterol (mmol/l) 6.379/1.09 6.319/0.99 6.439/1.14 0.891
Hypercholesterolemia(% (n )) 42.9 (6) 39.1 (18) 46.4 (13) 0.868
HDL cholesterol (mmol/l) 1.519/0.23 1.559/0.32 1.609/0.35 0.599
LDL cholesterol (mmol/l) 4.379/0.93 4.219/0.94 4.319/1.05 0.745
Triglycerides (mmol/l) 1.079/0.47 1.239/0.56 1.169/0.76 0.677
Apolipoprotein A1 (g/l) 1.419/0.17 1.469/0.25 1.479/0.21 0.659
Apolipoprotein B (g/l) 0.919/0.19 0.929/0.18 0.929/0.23 0.997
Atherosclerotic severity score 1.939/0.92 1.249/0.85 1.439/0.84 0.028
HDL, high density lipoprotein; LDL, low density lipoprotein. Hypercholesterolemia, total cholesterol /6.5 mmol/l. Significance is
based on analysis of covariance, age as covariate.
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affect the atheroprotective roles of circulating
estrogens [3]. It has been speculated that the PvuII
II polymorphism affects the splicing of ESR1
mRNA, resulting in the alteration of protein
expression [14,30] or that the polymorphism is
linked to some other polymorphism relevant to
protein expression [14]. Since the studied poly-
morphism is intronic in nature [16], it is most
probable that it is in linkage disequilibrium with a
mutation elsewhere in the ESR1 gene. The me-
chanism how the ESR1 PvuII polymorphism
affects signalling via ESR1 is not known, but the
variant forms are strongly associated with the area
of advanced atherosclerotic lesions. This supports
the hypothesis that at least some variation in
ESR1 gene may affect how the atheroprotective
Table 2
Baseline and follow-up lipid levels and atherosclerosis severity score in postmenopausal women among treatment groups
Variable and unit HRT-EVP (n/ 26) HRT-EV (n/ 32) C (n/ 30) P -value
Total cholesterol (mmol/l)
Baseline 5.799/0.87 6.559/0.95 6.649/1.10
Follow-up 5.649/0.81 6.109/0.86 6.249/0.97
D /0.169/0.63 /0.449/0.64 /0.409/0.73 0.271
HDL cholesterol (mmol/l)
Baseline 1.499/0.24 1.669/0.37 1.529/0.30
Follow-up 1.789/0.38 1.779/0.43 1.689/0.41
D 0.299/0.27* 0.119/0.33 0.169/0.26 0.024
LDL cholesterol (mmol/l)
Baseline 3.959/0.88 4.249/0.87 4.569/1.06
Follow-up 3.439/0.78 3.659/0.85 3.919/0.89
D /0.529/0.62 /0.589/0.73 /0.649/0.67 0.943
Triglycerides (mmol/l)
Baseline 0.799/0.23 1.449/0.67 1.259/0.62
Follow-up 0.969/0.41 1.499/0.49 1.449/0.65
D 0.179/0.28 0.069/0.70 0.189/0.52 0.609
Apolipoprotein A1 (g/l)
Baseline 1.359/0.15 1.579/0.26 1.429/0.17
Follow-up 1.929/0.31 2.089/0.32 1.929/0.26
D 0.579/0.26 0.519/0.24 0.509/0.19 0.381
Apolipoprotein B (g/l)
Baseline 0.829/0.16 0.979/0.17 0.959/0.22
Follow-up 1.219/0.23 1.349/0.22 1.389/0.29
D 0.399/0.14 0.379/0.16 0.439/0.17 0.285
Atherosclerotic severity score
Baseline 1.319/0.84 1.139/0.79 1.809/0.89
Follow-up 3.199/1.36 2.919/1.35 4.309/1.80
D 1.889/1.24** 1.789/1.18*** 2.509/1.36 0.096
HDL, high density lipoprotein; LDL, low density lipoprotein. C, controls; EV, estradiol valerate, 2.0 mg/day; P, levonorgestrel, 0.25
mg/day. The D was calculated as follows:
D
Xn
i1
(follow-upibaselinei)=n
i , number of subgroup subjects. Age was used as covariate.
* P/0.071 EVP vs. C.
** P/0.084 EVP vs. C.
*** PB/0.05 EV vs. C.
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Table 3
Baseline and follow-up lipid levels and atherosclerosis severity score according to ESR1 Pvu II genotypes and treatment groups
HRT-EVP HRT-EV C
P/P (n/ 5) P/p (n/ 14) p/p (n/ 7) P/P (n/ 3) P/p (n/ 19) p/p (n/ 10) P/P (n/ 6) P/p (n/ 13) p/p (n/ 11)
Total cholesterol (mmol/l)
Baseline 5.609/1.12 5.829/0.94 5.899/0.61 6.339/0.72 6.609/0.77 6.509/1.35 7.039/0.85 6.409/1.17 6.709/1.16
Follow-up 5.609/1.07 5.769/0.71 5.419/0.88 5.879/0.91 6.189/0.58 6.039/1.28 6.539/0.68 6.049/0.92 6.319/1.16
D 0.009/0.39 /0.069/0.72 /0.479/0.51 /0.469/0.43 /0.439/0.65 /0.479/0.73 /0.509/0.31 /0.369/0.72 /0.399/0.9
Triglycerides (mmol/l)
Baseline 0.819/0.28 0.849/0.23 0.689/0.20 1.089/0.33 1.449/0.40 1.539/1.08 1.289/0.59 1.359/0.78 1.139/0.43
Follow-up 1.009/0.28 0.979/0.36 0.909/0.59 1.399/0.14 1.539/0.45 1.459/0.63 1.519/0.72 1.519/0.74 1.319/0.55
D 0.209/0.20 0.139/0.25 0.239/0.40 0.319/0.29 0.099/0.48 /0.089/1.09 0.229/0.65 0.179/0.65 0.189/0.26
HDL cholesterol (mmol/l)
Baseline 1.379/0.10 1.509/0.26 1.559/0.29 1.869/0.20 1.589/0.38 1.759/0.36 1.479/0.13 1.559/0.32 1.519/0.37
Follow-up 1.689/0.44 1.789/0.42 1.869/0.28 2.049/0.29 1.729/0.48 1.799/0.37 1.599/0.33 1.719/0.44 1.699/0.45
D 0.319/0.35 0.279/0.27 0.319/0.24 0.199/0.24 0.149/0.39 0.049/0.25 0.129/0.31 0.159/0.25 0.199/0.26
LDL cholesterol (mmol/l)
Baseline 3.879/0.99 3.949/1.01 4.039/0.60 3.989/0.67 4.379/0.73 4.079/1.17 4.999/0.71 4.249/1.12 4.699/1.11
Follow-up 3.479/1.01 3.559/0.71 3.159/0.78 3.199/0.65 3.769/0.67 3.589/1.18 4.269/0.64 3.649/0.82 4.029/1.04
D /0.409/0.65 /0.399/0.62 /0.889/0.52 /0.799/0.43 /0.609/0.85 /0.489/0.58 /0.729/0.36 /0.599/0.65 /0.669/0.85
Apolipoprotein A1 (g/l)
Baseline 1.319/0.13 1.359/0.14 1.389/0.19 1.589/0.23 1.579/0.31 1.599/0.18 1.419/0.12 1.419/0.18 1.439/0.21
Follow-up 1.959/0.36 1.919/0.35 1.929/0.24 2.249/0.19 2.089/0.34 2.039/0.31 1.889/0.21 1.949/0.26 1.929/0.32
D 0.649/0.27 0.569/0.29 0.549/0.20 0.669/0.05 0.519/0.27 0.459/0.21 0.469/0.23 0.539/0.18 0.499/0.20
Apolipoprotein B (g/l)
Baseline 0.809/0.18 0.849/0.18 0.799/0.13 0.869/0.15 0.979/0.13 0.989/0.24 1.029/0.19 0.929/0.21 0.959/0.25
Follow-up 1.259/0.26 1.249/0.23 1.149/0.22 1.209/0.23 1.379/0.17 1.309/0.28 1.509/0.21 1.329/0.28 1.389/0.33
D 0.459/0.14 0.399/0.13 0.359/0.16 0.349/0.17 0.409/0.15 0.339/0.18 0.489/0.04 0.409/0.15 0.449/0.22
AS :
Baseline 1.809/0.84 1.149/0.95 1.299/0.49 1.339/1.53 1.119/0.66 1.109/0.88 2.339/0.52 1.549/0.97 1.829/0.87
Follow-up 3.409/1.67 2.869/1.35 3.719/1.11 3.679/2.08 3.009/1.33 2.509/1.18 5.339/1.75 4.319/1.93 3.739/1.56
Da 1.609/1.14 1.719/1.27 2.439/1.27 2.339/0.58 1.899/1.37 1.409/0.84 3.009/1.67 2.779/1.30 1.919/1.14
HDL, high density lipoprotein; LDL, low density lipoprotein; AS, atherosclerotic severity score. The D was calculated as follows:
D
Xn
i1
(follow-upibaselinei)=n
i , number of subgroup subjects.
a Borderline significant genotype-by-treatment interaction for AS (P/0.078). Significant genotype-by-treatment interaction (HRT-EVP and control groups) for AS
(P/0.034). Age was used as covariate.
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actions of estrogens are mediated to artery wall
cells.
Estrogens suppress arterial smooth muscle cell
proliferation and migration [31], and they increase
the synthesis of collagen, pro-collagen, and elastin
in the arterial intima [32]. Estrogens reduce the
accumulation of cholesterol in the arterial wall
[33,34], and protect LDL from oxidation [35].
Since estrogens have many anti-atherogenic ef-
fects, it is possible that impaired effects of estro-
gens may lead to progression of atherosclerosis
and higher risk for coronary thrombosis. In fact, a
recent study suggested an association between
diminished estrogen receptor expression and the
occurrence of premature coronary atherosclerosis
[13].
In the present study we show that a significant
genotype-by-treatment (HRT-EVP and control
groups) interaction for AS. In response HRT-
EVP, subjects with P/P, had a less increase in AS,
compared with those with P/p and p/p genotypes.
We also found that both HRT and ESR1 PvuII
genotype had effect on AS by RANOVA.
In conclusion, our study shows that both long-
term HRT-EV alone and combined HRT-EVP are
associated with less severe atherosclerotic lesions
as compared to controls not taking HRT. Our
study also indicated that long-term HRT and
ESR1 PvuII genotype have effect on AS in
postmenopausal women. ESR1 PvuII polymorph-
ism is associated with the progression of AS to
treatment with HRT-EVP. Subjects with P/P
genotype had a less progression in AS. The effect
of HRT-EVP in postmenopausal women on pro-
gression of AS may be determined in part by the
genotype of ESR1 PvuII. Our study points out
Fig. 1. The main effect of ESR1 Pvu II genotypes, HRT, and time on atherosclerotic severity score during 5-year follow-up analyzed
by repeated measures ANOVA. ESR1 Pvu II, estrogen receptor 1 Pvu II; HRT, hormone replacement therapy. EV, estradiol valerate,
2.0 mg/day; P , levonorgestrel, 0.25 mg/day. Atherosclerotic severity score is estimated from aorta and carotid artery by sonography.
Age was used as covariate.
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that the ESR1 gene is an interesting candidate
gene behind the pathogenesis of acute coronary
events, although the actual gene variant causing
altered function remains to be solved.
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Carbohydrate-deficient transferrin and gamma-
glutamyltransferase are inversely associated with lipid
markers of cardiovascular risk
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Abstract Background A variety of epidemiological studies have suggested a U-shaped association
between alcohol consumption and atherosclerosis progression and incidence events.
Moderate intake of alcohol is considered beneficial, whereas heavy drinking increases
cardiovascular disease risk.
Methods Alcohol and cardiovascular risk-related laboratory tests were carried out in 70
consecutive male employees in connection with an occupational health survey in 1996.
Carbohydrate-deficient transferrin (CDT) and gamma-glutamyltransferase (GGT) were
used as markers for alcohol consumption. The subjects were divided into quartiles on the
basis of CDT or GGT value.
Results The highest CDT quartile had significantly higher serum high-density lipoprotein
(HDL)-cholesterol (P< 0·05) than the lowest quartile. The highest GGT quartile had
significantly higher serum total cholesterol (P <0·01), lower serum HDL-cholesterol
(P <0·05), higher serum low-density lipoprotein (LDL)-cholesterol (P< 0·01) and higher
serum triglyceride (P <0·01) than the lowest quartile.
Conclusions An explanation for the findings is that high alcohol consumption without
significant liver induction increases the level of HDL-cholesterol, whereas high alcohol
consumption with induction of liver may have adverse effects on lipoprotein metabolism.
The results were interpreted to indicate that CDTand GGT detect different populations of
drinkers in regard to cardiovascular lipid risk factors.
Keywords Carbohydrate-deficient transferrin, cholesterol, ethanol, gamma-glutamyl-trans-
ferase, lipids.
Eur J Clin Invest 1998; 28 (10): 793–797
Introduction
Population studies have suggested that moderate long-
lasting intake of alcohol may help to protect the heart
from coronary artery disease [1]. This is partly thought
to be mediated by the effects of alcohol on lipoprotein
metabolism, because alcohol consumption has generally
been associated with an increase in high-density lipoprotein
(HDL)-cholesterol [2] and/or decrease in low-density lipo-
protein (LDL)-cholesterol [3]. In addition, alcohol intake
may reduce blood coagulation and enhance the dissolution
of blood clots [4,5]. In contrast, heavy drinking and
alcoholism can result in cardiomyopathy, arrhythmias and
increased blood pressure [6]. The toxic effects of alcohol on
lipoprotein metabolism, probably through its action in the
liver, may include fatty liver and, in the later phase, hyper-
cholesterolaemia and decreased HDL-cholesterol [7].
Carbohydrate-deficient transferrin (CDT) and gamma-
glutamyltransferase (GGT) are generally considered to be
the most useful laboratory markers for high alcohol con-
sumption [8,9]. The traditionally used GGT is known to
reflect liver status, and the values are increased by alcohol
and other liver microsome-inducing agents, by most
hepatobiliary disorders and by obesity, diabetes mellitus
and hypertriglyceridaemia. As those two markers do not
correlate with each other [8–12], they may offer an addi-
tional viewpoint for studying the effect of alcohol on lipids.
In the present study, differences in total CDT and GGT
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values were compared with the lipid profile of male
employees in a routine occupational health survey.
Subjects and methods
Alcohol and lipid profile-related laboratory tests were
carried out in 70 consecutive non-alcoholic male employ-
ees (mean age 45 years, range 37–58 years, SE 0·7 years) in
connection with an occupational health survey in 1996.
The employees were both blue-collar and white-collar
workers from a board machine manufacturing factory.
The sera were stored at –208C until the first analysis.
The activity of serum GGTwas determined according to
the recommendations of the Scandinavian Society for
Clinical Chemistry and Clinical Physiology [13]. Total
cholesterol and HDL-cholesterol were determined by an
enzymatic colorimetric method (CHOD-PAP, Labsystems,
Finland, or Boehringer Mannheim, Germany) in a stan-
dardized laboratory. Triglycerides were determined by
enzymatic hydrolysis of triglycerides with subsequent
determination of liberated glycerol by colorimetry (Boeh-
ringer Mannheim). LDL-cholesterol was calculated
according to the Friedewald formula. The CDT in the
sera was determined in duplicate determinations using the
CDTect RIA kit (Pharmacia Diagnostics, Uppsala,
Sweden). Body mass index (BMI) was calculated as
weight (kg)/height2 (m2). Alcohol consumption was also
estimated by the AUDIT test, with a score of 8 points or
more indicating high alcohol consumption [14,15]. A
current smoker was defined as a person who now smokes
daily. In addition, a trained nurse/physician reported drug
use, known diseases and relevant clinical symptoms of the
employees.
The statistical evaluation was carried out with Statistica
software (Statsoft, Tulsa, OK, USA, 1996 version).
Estimated significance was based on ANOVA.
Employees were divided into quartiles on the basis of
CDT value or GGT value (Table 1). The lowest CDT
quartile (Q1) had serum values of under 12 U L
¹1, the
second quartile (Q2) was from 12 to under 14 U L
¹1, the
third quartile (Q3) was from 14 to under 16 U L
¹1 and the
highest CDT quartile (Q4) had values of 16 U L
¹1 or over.
The serum GGT values for the GGT quartiles were: Q1,
under 28 U L¹1; Q2, 28–40 U L
¹1; Q3, over 40 U L
¹1 but
under 69; Q4, 69 U L
¹1 or over. There was an overlap of
four men (6%) between the lowest CDT and lowest GGT
quartiles, and an overlap of four men (6%) between the
highest quartiles, indicating that the extreme quartiles
represent populations distinct from each other.
Table 1 presents background characteristics and lipid
values of the CDT and GGT quartiles. There was a
statistically significant difference in the AUDIT test
scores between the extreme GGT quartiles. There was a
trend of increased AUDIT test values between the extreme
CDT quartiles, but it did not reach statistical significance
(6·2 vs. 7·3 points respectively). The extreme CDT quar-
tiles were similar in regard to BMI, age and smoking. The
extreme GGT quartiles differed significantly in BMI values
but were similar in regard to age and smoking. None of the
participants had diabetes and none was on lipid-lowering
medication.
Results
To visualize the relation of markers of alcohol consumption
with serum lipid levels, the subjects were divided into
quartiles according to CDT and GGT. Figure 1 represents
cardiovascular lipid risk factors in the extreme quartiles of
CDT and GGT values. The highest CDT quartile had
significantly higher HDL-cholesterol (P<0·05) (Fig. 1B
and Table 1) than the lowest quartile. The highest GGT
quartile had significantly higher total cholesterol (P <0·01)
Q 1998 Blackwell Science Ltd, European Journal of Clinical Investigation, 28, 793–797
Figure 1 Cholesterol, HDL-cholesterol
and triglycerides (mmol L¹1) in the
lowest (1) and highest (4) CDT and
GGT quartiles. CDT quartiles: lowest
# 12 U L¹1, highest $ 16 U L¹1. GGT-
quartiles: lowest <29 U L¹1, highest
$ 75 U L¹1. The larger box, 6 1·00 SE;
the vertical lines, 6 1·96 SE; the small
box, mean. Elevated CDT seems to have
positive effects on lipid values, whereas
elevated GGT seems to have adverse
effects on them.
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(Fig. 1D, Table 1), lower HDL-cholesterol (P< 0·05) (Fig.
1E, Table 1), higher LDL-cholesterol (P< 0·05)(Table 1)
and higher triglyceride (P< 0·01) (Fig. 1F and Table 1)
than the lowest quartile. There was no statistically signifi-
cant difference between the extreme CDT quartiles in the
total serum cholesterol (Fig. 1A and Table 1) and trigly-
ceride values (Fig. 1C, Table 1). There was no statistically
significant difference between the extreme CDT quartiles
in LDL-cholesterol values (Table 1).
The highest CDT quartile and the lowest GGT
quartile seemed to be associated with a favourable lipid
profile, and the lowest CDT quartile and the highest GGT
quartile were associated with an unfavourable lipid profile.
We therefore additionally compared the lipid values in
subjects who had a higher half CDT value and a lower
half GGT value (CDT Q3–4/GGT Q1–2) or a lower half
CDT value and a higher half GGT value (CDT Q1–2/GGT
Q3–4) (Table 2). The favourable CDT Q3–4/GGT Q1–2
group had significantly lower cholesterol values, higher
HDL-cholesterol values and lower triglyceride values
than the unfavourable CDT Q1–2/GGT Q3–4 group
(Table 2).
Discussion
CDT has proved to be a useful marker of high continuous
alcohol consumption [8,9,16]. We show that the subjects in
the highest CDT quartile had an elevated HDL value
Table 1 Background characteristics and lipid values of the CDT and GGT quartiles among 70 consecutive male employees
Q1 Q2 Q3 Q4 Significance
CDT
n 17 17 18 18
Age 43·0 6 1·2 44·9 6 1·6 44·9 6 1·4 45·3 6 1·5 P ¼ NS
BMI 26·1 6 0·7 27·2 6 0·9 25·5 6 0·7 26·4 6 0·7 P ¼ NS
AUDIT score 6·2 6 0·8 6·6 6 1·1 5·9 6 0·8 7·3 6 1·0 P ¼ NS
AUDIT score $ 8 35% 41% 33% 50%
Smokers 12% 29% 22% 11% P ¼ NS
Cholesterol 5·82 6 0·20 6·12 6 0·25 5·96 6 0·28 5·56 6 0·31 P ¼ NS
HDL-cholesterol 0·99 6 0·06 1·01 6 0·07 1·15 6 0·10 1·24 6 0·09 P <0·05
LDL-cholesterol 3·92 6 0·19 4·10 6 0·20 3·91 6 0·32 3·53 6 0·26 P ¼ NS
Triglycerides 2·01 6 0·25 2·28 6 0·46 1·97 6 0·30 1·76 6 0·34 P ¼ NS
GGT
n 16 17 19 18
Age 42·5 6 1·3 45·1 6 1·3 45·0 6 1·6 45·3 6 1·5 P ¼ NS
BMI 23·4 6 0·7 25·5 6 0·5 27·7 6 0·6 28·1 6 0·7 P <0·01
AUDIT score 5·6 6 1·0 6·1 6 0·9 5·9 6 0·9 8·3 6 0·8 P <0·05
AUDIT score $ 8 19% 29% 37% 78%
Smokers 19% 6% 16% 33% P ¼ NS
Cholesterol 5·13 6 0·21 6·06 6 0·20 5·85 6 0·18 6·36 6 0·36 P <0·01
HDL-cholesterol 1·26 6 0·08 1·23 6 0·10 0·95 6 0·05 1·01 6 0·08 P <0·05
LDL-cholesterol 3·39 6 0·22 3·98 6 0·20 3·99 6 0·17 3·99 6 0·36 P <0·01
Triglycerides 1·07 6 0·10 1·87 6 0·24 1·99 6 0·29 2·98 6 0·44 P <0·01
Means and SE of the CDTand GGT quartiles among non-alcoholic male employees. Statistical significance was determined between the
lowest (Q1) and highest (Q4) quartiles. NS, not significant.
Table 2 Lipid values of subjects belonging to opposite halves of CDT and GGT
CDT Q1–2 /GGT Q3–4 (n ¼ 20) CDT Q3–4 /GGT Q1–2 (n ¼ 20) Significance
Age 43·2 6 1·34 42·7 6 1·2 P ¼ NS
BMI 27·8 6 0·5 23·8 6 0·5 P<0·01
AUDIT score 7·6 6 0·8 6·6 6 0·8 P ¼ NS
AUDIT score $ 8 45% 25%
Smokers 35% 20% P ¼ NS
Cholesterol 6·25 6 0·22 5·56 6 0·25 P<0·05
HDL-cholesterol 0·96 6 0·06 1·36 6 0·08 P<0·01
LDL-cholesterol 4·22 6 0·19 3·64 6 0·23 P ¼ NS
Triglycerides 2·37 6 0·39 1·23 6 0·15 P<0·01
Comparison of means and SE of lipid values in subjects who have a lower half CDT value and a higher half GGT value (CDT
Q1–2 /GGT Q3–4) or a higher half CDT value and a lower half GGT value (CDT Q3–4/GGT Q1–2). NS, not significant.
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compared with the lowest quartile. This is consistent with
the hypothesis that the ingestion of alcohol has a protective
effect against coronary heart disease, presumed to be
mediated mainly through elevation of HDL values
[1,6,17]. An impact of alcohol on sialylated lipoproteins,
such as LDL, very low-density lipoprotein (VLDL) and
HDL [18], may be one of the mechanisms leading to
increased HDL values in the highest CDT quartile. It
appears that CDT is also associated with factors related
to insulin/glucose metabolism, because a previous study
has shown that triglyceride concentrations in diabetic
individuals with high CDT values are low rather than
high [19].
In contrast to the beneficial effects of moderate ingestion
of alcohol, excessive alcohol consumption has been shown
to lead to derangements of lipid and lipoprotein meta-
bolism. This is due to the toxic effects of ethanol on
peripheral and hepatic lipid metabolism, leading to
hypercholesterolaemia, decreased HDL-cholesterol and
hypertriglyceridaemia [7]. Ethanol-induced changes in
hepatic metabolism are hypothesized to be the basis for
delayed lipoprotein clearance [20]. Elevation of GGT in
serum probably reflects its induced hepatic synthesis
and increased transport to the liver plasma membranes
[21,22]. Thus, alcohol-induced GGT [9,16] may offer a
tool to detect non-beneficial effects of alcohol on cardio-
vascular lipid risk factors. GGT has previously been
shown to have a positive association with total serum
cholesterol, HDL-cholesterol and triglycerides [23]. How-
ever, we report here decreased HDL-cholesterol, which is
more in line with the chronic effects of high alcohol
consumption on lipoprotein metabolism [7]. There is a
known relationship between GGT values and BMI [23].
This was also apparent in the present study, with subjects in
the highest GGT quartile having statistically higher BMI
values than those in the lowest quartile. Nevertheless, this
quartile had a considerably high proportion of alcohol
abusers, as supported by the high mean AUDIT-score
and the high percentage of subjects with an AUDIT score
of $ 8.
In conclusion, the present results indicate that high
alcohol consumption with normal serum level of GGT is
associated with increased serum HDL-cholesterol, whereas
high alcohol consumption with liver induction leading
to elevated GGT may have adverse effects on lipo-
protein metabolism, including hypercholesterolaemia,
decreased HDL-cholesterol, increased LDL-cholesterol
and hypertriglyceridaemia. CDT and GGT are indepen-
dently correlated with heavy drinking [8–12], and they
seem to detect different populations of drinkers in
regard to lipid metabolism. The observation may help
to understand different biochemical effects of alcohol
consumption on lipids.
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Abstract
Background: Moderate consumption of alcohol may reduce mortality from vascular diseases. The beneficial effects of alcohol
may partly be mediated by its effects on lipoprotein metabolism. We studied the connection between alcohol consumption and the
serum lipid profile from a well-documented national health program study. Methods and results: Carbohydrate-deficient
transferrin (CDT) and gamma-glutamyl-transferase (GGT) were used as biochemical markers for alcohol consumption. The
laboratory analyses were carried out on 5675 subjects (3097 males and 2578 females). The subjects were divided into quartiles on
the basis of CDT or GGT value. The highest CDT quartile and the lowest GGT quartile seemed to be associated with a favorable
lipid profile and the lowest CDT quartile and the highest GGT quartile were associated with an unfavorable lipid profile. Serum
high density lipoprotein (HDL) cholesterol values were significantly higher and triglycerides lower with increasing serum CDT
concentrations for both men and women. Increasing serum GGT was associated with higher serum total cholesterol and higher
triglycerides in both men and women and lower HDL cholesterol in men. Conclusions: CDT and GGT seem to detect different
populations of subjects in regard to lipid metabolism. These observations may lead to a better understanding of the effects of
alcohol consumption on lipids as well as mechanisms behind favorable and detrimental effects of alcohol on vascular diseases.
Condensed abstract: Carbohydrate-deficient transferrin (CDT) and gamma-glutamyl-transferase (GGT) were used as biochemical
markers for alcohol consumption. A total of 3097 males and 2578 females were divided into quartiles on the basis of their CDT
or GGT values. The highest CDT quartiles had higher HDL and lower triglycerides, whereas the highest GGT quartiles appeared
to be associated with higher total cholesterol and triglycerides in both genders and lower HDL in men. CDT and GGT seem to
detect different populations of subjects in regard to lipid metabolism. These observations may have important clinical and public
health implications. © 2001 Elsevier Science Ireland Ltd. All rights reserved.
Keywords: CDT; GGT; Ethanol; Cholesterol; Lipids
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1. Introduction
Several studies have shown that moderate consump-
tion of alcohol reduces mortality from vascular diseases
[1]. There seems to be a U-shaped association between
alcohol consumption and coronary heart disease
(CHD) incidence events [2]. The beneficial effect of
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alcohol may partly be mediated by its effects on lipo-
protein metabolism, since alcohol consumption has
generally been associated with an increase of high den-
sity lipoprotein (HDL) cholesterol [3,4] and occasion-
ally, a decrease of low density lipoprotein (LDL)
cholesterol [5]. Alcohol intake may also reduce blood
coagulation [6]. Excessive alcohol use and alcoholism
have detrimental effects on the cardiovascular system
and are associated with increased occurrence of stroke,
abdominal aneurysms, hypertension, alcoholic car-
diomyopathy, arrhythmias, as well as increased CHD
[7]. The unfavorable effects of alcohol on lipoprotein
metabolism include hypertriglyceridemia and fatty liver,
and in the later phase, hypercholesterolemia and de-
creased HDL cholesterol [8].
Serum carbohydrate-deficient transferrin (CDT) and
gamma-glutamyl-transferase (GGT) are generally con-
sidered to be useful laboratory markers for high alcohol
consumption [9,10]. Transferrin is a monomeric, iron-
binding glycoprotein, which is synthesized in the liver.
Chronic alcohol consumption leads to deficiencies in
the carbohydrate content of the protein by a yet un-
known mechanism [11]. GGT is known to reflect liver
function and its activity in serum is increased by alco-
hol and other liver microsomal inducing agents, in most
hepatobiliary disorders, obesity, diabetes mellitus and
hypertriglyceridemia. Elevation of GGT in serum prob-
ably reflects its enhanced hepatic synthesis rate, in-
creased transport to the liver plasma membranes, as
well as liver injury [12].
Both CDT and GGT are markers of alcohol con-
sumption, but their serum values do not correlate with
each other [13,14] and may, thus, reflect different drink-
ing patterns [15]. We have previously reported, in a
pilot study of 70 men, that high alcohol consumption
with an elevated serum CDT concentration was associ-
ated with increased serum HDL cholesterol, whereas
high alcohol consumption with an elevated serum GGT
activity had adverse effects on lipoprotein metabolism,
including hypercholesterolemia, decreased HDL choles-
terol, increased LDL cholesterol and hypertriglyce-
ridemia [16]. In the present study, we wished to
determine whether this finding could be substantiated in
a large population and in both genders. In the effort to
reduce population cholesterol levels, it is of great inter-
est to study the effect of alcohol consumption on the
serum lipid profile from a well-documented national
health program study population [17].
2. Methods
2.1. Subjects
The National Public Health Institute of Finland has
performed large cross-sectional population surveys, the
FINRISK studies, related to the risk factors of coro-
nary artery disease every 5 years beginning in 1972 [17].
The 1997 FINRISK study was conducted in five geo-
graphic areas: Helsinki–Vantaa region in southern Fin-
land, Turku–Loimaa region in southwestern Finland,
Kuopio and North Karelia provinces in eastern Fin-
land, and Oulu province in northern Finland. In each
study area, an age- and gender-stratified random sam-
ple of 2000 subjects was drawn from the population
aged between 25 and 64 years. In addition, a random
sample of 500 men and 250 women was drawn in
Helsinki–Vantaa region and in North Karelia province
from the 65–74 years age-group. The present study is a
sub-study of the 1997 FINRISK project. The total
sample size was 11 500. The participation rate was 71%
among men and 76% among women. Subjects who had
missing data on serum lipids, GGT or CDT, who had
diabetes, who were pregnant or who were using choles-
terol lowering medication or hormonal treatment were
excluded. Thus, 3097 males and 2578 females were
included in the study. The present study was conducted
according to the Helsinki Declaration of 1975 on Hu-
man Experimentation and was approved by the Ethical
Committee of Primary Health Clinics in Finland. All
participants gave informed consent to scientific use of
the data and samples collected in the study.
2.2. Measurements
The survey included a self-administered question-
naire, which was sent to the subjects in advance, includ-
ing 165 questions about previous and existing diseases,
socioeconomic background, smoking habits, occupa-
tional status and alcohol intake. The participants re-
turned the questionnaires to the survey site.
Subsequently, the participants’ height, weight and
blood pressure were measured using standard proce-
dures and a venous blood specimen was taken. Body
mass index (BMI) was calculated as the ratio of weight
(kg) to height squared (m2).
Quantitative estimation of the alcohol intake was
carried out by using 12 structured questions to deter-
mine the amount and frequency of drinking. The mea-
sure for average weekly intake included the following
drinks: beer, cider, liquor, long drink and wine. The
total mean consumption of all alcoholic drinks was
used, expressed as grams of pure ethanol per week. The
variable ‘number of smokes per day’ was computed by
adding up the numbers of filter cigarettes, non-filter
cigarettes, self-made cigarettes, pipe-fulls and cigars
smoked on an average day for all subjects who reported
having smoked within 1 month prior to the survey.
‘Physical activity’ was determined as a session of
leisure-time exercise resulting in shortness of breath and
sweating (times:week).
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CDT concentrations in serum samples were analyzed
by a double antibody kit (CDTect™, Pharmacia and
Upjohn Diagnostics, Uppsala, Sweden) according to
the manufacturer’s instructions. The test is based on
anion exchange chromatography and radioim-
munoassay [9,18] and has a detection limit of 1 U:l and
a measuring range of 5–300 U:l. The calibration of the
test was assessed from a five-point standard curve
derived from the displacement of 125I-CDT from the
antibody by known amounts of human transferrin,
within the interval 0–100 U:l. CDTect gives the results
in units per liter, which is comparable to mg:l in serum
(1 U CDT refers to :1 mg transferrin). The activity of
serum GGT was determined according to the recom-
mendations of the Scandinavian Society for Clinical
Chemistry and Clinical Physiology [19]. Total and
HDL cholesterol were determined from fresh serum
samples by an enzymatic method (CHOD-PAP,
Boehringer Mannheim, Mannheim, Germany). Triglyc-
erides were measured by a fully enzymatic method
(GPO-PAP, Boehringer-Mannheim) using the Olli-C
analyzer (Konelab, Espoo, Finland). The blood sam-
ples were analyzed in the laboratory of the National
Public Health Institute in Helsinki, Finland and in the
Pharmacia and Upjohn laboratory in Uppsala, Sweden.
External quality assessments were made in collabora-
tion with the World Health Organization Lipid Re-
search Center in Prague.
Because the data was not normally distributed, sub-
jects of both genders were divided into quartiles on the
basis of CDT concentration or GGT activity (Tables 1
and 2). The statistical evaluation was carried out with
Statistica software (Statsoft, Inc., Tulsa, OK, 1996 ver-
sion). Estimated significance was based on analysis of
variance (ANOVA).
3. Results
The serum concentrations of lipids in the CDT quar-
tiles together with alcohol consumption during the pre-
vious week and confounding variables (age, BMI and
smoking) are presented in Table 1. Serum CDT concen-
trations were positively associated with higher alcohol
consumption and smoking and lower BMI in both
genders. There was no significant difference in physical
activity between the different CDT quartiles. Serum
CDT concentrations were negatively associated with
age in women, but not in men. Serum HDL cholesterol
values was significantly higher and triglycerides lower
with increasing serum CDT concentrations for both
men and women. These results remained significant
even after adjustment for age, BMI and smoking.
Serum total cholesterol decreased with increasing CDT
concentrations in women, but not in men. The decrease
of total cholesterol in women disappeared, however,
after adjustment for age, BMI and smoking. Serum
CDT concentration and GGT activity were positively
associated in men and negatively associated in women,
but the negative association in women did not remain
significant after adjustment for age, BMI and smoking
(Table 1).
The data for the GGT quartiles are presented in
Table 2. Increases in serum GGT activity were posi-
tively associated with higher alcohol consumption,
smoking, age, and BMI in both genders. There was a
significant difference in physical activity between the
different GGT quartiles in both genders, but it disap-
peared after adjustment for age, BMI and smoking.
Increasing serum GGT was associated with higher
serum total cholesterol, slightly lower HDL cholesterol,
and higher triglycerides. The small decrease of HDL
cholesterol in women with increasing GGT lost its
significance after adjustment for age, BMI and smok-
ing. The corresponding decrease of HDL cholesterol in
men and the other lipid results remained statistically
significant even after adjustment for age, BMI and
smoking. After this adjustment, serum GGT activity
and CDT concentration were positively associated in
men but not in women.
The unadjusted data for lipids in the CDT quartiles
are shown in Fig. 1. It appears that increased CDT is
associated with a favorable lipid profile, including
higher HDL cholesterol and lower triglycerides. How-
ever, the decrease of total cholesterol with increased
CDT in women was not significant after adjustment for
age, BMI and smoking in the statistical analysis. In
contrast to the favorable association of increased CDT
with lipid risk factors, increase in GGT quartiles ap-
peared to affect the lipid profile unfavorably. There
were higher concentrations of total cholesterol and
triglycerides for both genders with increasing GGT
activity. The differences in HDL cholesterol between
GGT quartiles were small in both men and women, but
still there was a statistically significant decrease of HDL
cholesterol in men even after adjustment for age, BMI
and smoking. We did not find any differential effects of
alcohol from various sources or frequency and quantity
per one occasion of drinking on CDT concentrations or
GGT activity (data not shown).
Since serum CDT concentration and GGT activity
seemed to be inversely associated with lipid markers of
cardiovascular risk, a comparison was made between
the lipid values in subjects who had a highest quartile
CDT and a lowest quartile GGT (CDT Q4:GGT Q1) or
a lowest quartile CDT and a highest quartile GGT
(CDT Q1:GGT Q4) (Table 3). The favorable CDT
Q4:GGT Q1 group had significantly lower cholesterol
and triglyceride values and higher HDL cholesterol
values than the unfavorable CDT Q1:GGT Q4 group in
both genders, even after adjustment for age and BMI.
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4. Discussion
This cross-sectional study was carried out to assess
the relation between the alcohol markers CDT and
GGT and the lipid profile. We show that with increas-
ing serum CDT concentrations, serum HDL cholesterol
values were significantly higher and triglycerides lower
in both men and women. The effect may partly be
caused by alcohol, since CDT correlated positively with
alcohol consumption. CDT has been extensively investi-
gated as a potent marker of alcohol abuse [10,20]. The
association of CDT with a favorable lipid profile is in
agreement with our earlier pilot study, conducted in
connection with a routine occupational health examina-
tion [16]. Numerous epidemiological studies have
shown with consistency that moderate alcohol intake
(variously defined but corresponding to one to four
drinks per day) decreases risk of CHD [1]. A part of the
protection is thought to be mediated by the effects of
alcohol on blood lipid metabolism, particularly in-
creases in HDL cholesterol [21]. A negative association
of CDT with triglycerides in the present study confirms
findings of a previous study, which showed that triglyc-
eride concentrations in diabetic individuals with high
CDT values were low rather than high [22].
Serum CDT was negatively associated with serum
total cholesterol in women, but this effect disappeared
after adjusting for age. This might be due to a decrease
Table 1
Background characteristics and serum lipid values in CDT quartilesa
Men (n3097) Q3 (n758) 13.4–16.6Q2 (n790) 11.0–13.3Q1 (n779) under 11.0 Q4 (n770) 16.7 U:l or Significance
U:l (mean (S.D.)) over (mean (S.D.))u:l (mean (S.D.))U:l (mean (S.D.))
P Pa
nsns5.57 (1.04)5.51 (1.07)Cholesterol 5.57 (1.02)5.48 (1.01)
(mmol:l)
*** ***1.16 (0.27)HDL-cholesterol 1.22 (0.28) 1.26 (0.29) 1.39 (0.35)
(mmol:l)
***1.79 (1.05) 1.72 (1.17)Triglycerides 1.66 (1.12) 1.47 (0.92) ***
(mmol:l)
82.9 (104.2)61.7 (94.1)54.9 (84.8) ******Alcohol last 136 (171)
week (g)
2.27 (1.95) 2.37 (3.40)Physical activity 2.39 (2.16) ns2.48 (2.47) ns
(times:week)
40.7 (39.5) 41.8 (82.1) 43.0 (52.6)GGT (IU:l) 49.9 (72.9) * **
Age 48.7 (13.5) 48.0 (13.6) 48.1 (13.7) 49.8 (13.5) *
27.0 (3.87) ***27.3 (3.71) 26.1 (3.92)Body mass index 26.9 (3.88)
(kg:m2)
2.99 (7.62) 3.39 (7.84)Smoking 4.10 (8.70) 6.85 (10.2) ***
(smokes:day)
Q1 (n618) under 13.9 Q4 (n659) 22.0 U:l orWomen Q2 (n634) 13.9–17.3 Q3 (n667) 17.4–21.9
U:l (mean (S.D.))(n2578) over (mean (S.D.))U:l (mean (S.D.)) U:l (mean (S.D.))
5.42 (1.05)5.58 (1.14)5.65 (1.12)Cholesterol ns***5.27 (0.99)
(mmol:l)
1.47 (0.32) 1.57 (0.33) 1.67 (0.34)1.41 (0.32) ***HDL-cholesterol ***
(mmol:l)
1.15 (0.70)Triglycerides 1.47 (1.00) 1.31 (0.68) ******0.98 (0.49)
(mmol:l)
Alcohol last 19.0 (35.0) 42.3 (60.1)25.9 (41.7) ***26.3 (49.8) ***
week (g)
ns2.37 (2.27) ns2.38 (2.05)Physical activity 2.40 (2.04)2.33 (2.24)
(times:week)
**26.9 (21.3) ns27.6 (66.4) 23.4 (29.0) 21.0 (15.5)GGT (IU:l)
42.1 (11.3) ***49.3 (13.7)Age 46.8 (13.6) 44.2 (12.6)
Body mass index ***28.0 (5.45) 26.7 (5.24) 25.2 (4.49) 24.2 (4.03)
(kg:m2)
1.89 (5.03)Smoking 1.80 (5.00) ***2.89 (6.53)1.73 (5.01)
(smokes:day)
a Pa, P-value adjusted to age, body mass index and smoking; ns, nonsignificant. Significance is based on ANOVA.
* PB0.05.
** PB0.01.
*** PB0.001.
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Table 2
Background characteristics and serum lipid values in GGT quartilesa
Q2 (n815) 22–30Men (n3097) Q1 (n758) under 22 IU:l Q3 (n790) 31–46 IU:l SignificanceQ4 (n734) 47 IU:l or
(mean (S.D.))IU:l (mean (S.D.))(mean (S.D.)) over (mean (S.D.))
P Pa
5.13 (0.96) 5.41 (0.93) 5.69 (0.99)Cholesterol 5.91 (1.10) *** ***
(mmol:l)
1.30 (0.29) 1.25 (0.29) 1.23 (0.31)HDL-cholesterol 1.25 (0.35) *** ***
(mmol:l)
Triglycerides 1.26 (0.70) 1.48 (0.84) 1.77 (1.09) 2.17 (1.36) *** ***
(mmol:l)
51.1 (74.3) 63.6 (84.7) 84.4 (115)Alcohol last 138 (176) *** ***
week (g)
2.46 (2.21) 2.53 (2.28)Physical activity 2.31 (2.07) 2.19 (3.50) * ns
(times:week)
14.4 (5.72) 14.9 (6.36)CDT (U:l) 15.6 (8.58)14.5 (5.59) ** ***
45.5 (14.5)Age 49.1 (14.0) 49.6 (13.3) 50.3 (11.9) ***
24.9 (3.06) 26.3 (3.46) 27.4 (3.71) 28.8 (4.17)Body mass index ***
(kg:m2)
Smoking 3.14 (7.05) 3.85 (8.20) 4.78 (9.00) 5.58 (10.4) ***
(smokes:day)
Q1 (n703) under 14 IU:l Q2 (n655) 15–18 Q3 (n632) 19–25Women Q4 (n588) 26 IU:l
IU:l (mean (S.D.))(mean (S.D.))(n2578) IU:l (mean (S.D.)) (mean (S.D.))
5.14 (1.00) 5.33 (1.02) 5.66 (1.10) 5.85 (1.10)Cholesterol *** ***
(mmol:l)
1.55 (0.31) 1.55 (0.32) 1.52 (0.36) 1.50 (0.38) * nsHDL-cholesterol
(mmol:l)
1.00 (0.50) 1.07 (0.56) 1.30 (0.67)Triglycerides 1.57 (1.07) *** ***
(mmol:l)
21.6 (33.3) 28.0 (43.7) 30.8 (48.7)Alcohol last 34.9 (64.7) *** ***
week (g)
2.42 (2.00) 2.52 (2.32) 2.39 (2.07)Physical activity 2.12 (2.18) * ns
(times:week)
18.8 (6.37) 18.3 (7.08) 17.4 (7.09) *** nsCDT (U:l) 19.5 (6.32)
43.6 (12.7) 47.5 (13.4) 51.2 (12.0) ***Age 40.9 (11.9)
24.0 (3.46) 25.0 (4.28) 26.6 (5.22)Body mass index 28.8 (5.75) ***
(kg:m2)
Smoking 1.54 (4.46) 1.92 (5.00) 2.30 (5.69) 2.70 (6.58) **
(smokes:day)
a Pa, P-value adjusted to age, body mass index and smoking; ns, nonsignificant. Significance is based on ANOVA.
* PB0.05.
** PB0.01.
*** PB0.001.
of CDT during menopause together with age-related
increase of serum total cholesterol [23]. Although the
subjects on hormone therapy were excluded from the
study, the effect of decrease of estrogen with menopause
could also affect the results.
The mechanism by which chronic alcohol consump-
tion causes an elevation of CDT levels in serum is still
not understood. It may be that the activities of glycosyl-
transferases involved in transferrin carbohydrate side
chain synthesis are diminished in the liver, at least in part,
due to enzyme inactivation by acetaldehyde [24]. Most
metabolic pathways of the liver are affected by alcohol,
as are several endocrine systems in the whole body. The
mechanism behind the association of CDT and lipo-
protein metabolism is also not clear at present. We report
that a decrease of BMI is associated with increased CDT
in both genders, which is known to have a favorable
effect on the lipid profile. However, even after adjusting
for BMI, there is a strong independent association of
CDT with HDL cholesterol and triglycerides. The base-
line values of CDT have been shown to be fairly constant
over time within the same individual, but there is some
variation between individuals even without any alcohol
consumption [25]. This could suggest that there is a yet
unknown mechanism that may influence both (hepatic)
CDT formation and lipoprotein metabolism.
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In contrast to the beneficial effects of moderate alco-
hol consuption on CHD risk, excessive alcohol intake
and alcoholism are associated with increased CHD risk.
Alcohol use is associated with lipoprotein metabolism
by hypertriglyceridemia and, once hepatic damage oc-
curs, serum HDL cholesterol levels may actually be
lower than normal [8]. Heavy alcohol consumption is
known to elevate both CDT concentrations and GGT
activity, but the contribution of drinking pattern to
these effects is not completely understood. Alcohol
consumption associated almost identically in the
present study with CDT and GGT and we did not find
any differential effects of alcohol from various sources
(beer, wines or spirits) or frequency and quantity per
one occasion of drinking on these markers. On the
other hand, it has previously been proposed that in
men, CDT levels may respond primarily to frequency
of drinking, whereas GGT may be influenced primarily
by drinking quantity per one occasion [15].
Unlike the CDT concentration, increasing serum
GGT activity was associated with higher serum total
cholesterol, and higher triglycerides in both genders.
The association of GGT with total cholesterol and
triglycerides may reflect deranged liver lipid metabolism
possibly associated with fatty liver formation. Alcohol
consumption is known to show a linear dose–response
relationship with HDL cholesterol, but this increase
may be modulated by the degree of liver injury [26].
Our observations agree with earlier studies showing no
positive correlation between GGT activity and HDL
cholesterol [27,28], although positive correlations have
been reported [29]. With increasing GGT, there was
actually a small decrease of HDL cholesterol values in
both genders, but in women this decrease lost its signifi-
cance after adjustment for age, BMI and smoking.
Increases in serum GGT activity were associated with
age and BMI in both genders, confirming earlier find-
ings [29,30].
With regard to serum CDT concentration and GGT
activity, an optimal lipid profile was observed in sub-
jects who belonged to the highest quartile CDT group
and also to the lowest quartile GGT group, even after
adjustment for age and BMI. It is possible that CDT is
an earlier phase marker of alcohol consumption than
GGT, and GGT might in fact reflect toxic effects of
ethanol on hepatic lipid metabolism, leading to hyperc-
holesterolemia, decreased HDL cholesterol and hyper-
triglyceridemia [8,30]. On the other hand, this
hypothesis is not supported by the fact that the average
self-reported alcohol consuption was 136 g per week for
Fig. 1. Cholesterol, HDL cholesterol and triglycerides (mmol:l) in the CDT- and GGT-quartiles in men and women. The larger box, 91.00 S.E.;
the vertical lines, 91.96 S.E.; the small box, mean.
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Table 3
Lipid values of subjects belonging to opposite extreme quartiles of CDT and GGTa
CDT Q4:GGT Q1 (S.D.) (n180)CDT Q1:GGT Q4 (S.D.) (n178) SignificanceMen
P Pa
5.19 (0.98) ***Cholesterol (mmol:l) ***5.90 (1.14)
1.42 (0.31) ***HDL-cholesterol (mmol:l) ***1.11 (0.28)
1.12 (0.49) **Triglycerides (mmol:l) ***2.35 (1.35)
Alcohol last week (g) 89.9 (109) 80.0 (94.1) ns ns
2.56 (2.54) ns2.11 (1.87) *Physical activity (times:week)
47.3 (14.8) nsAge 49.9 (12.4)
24.3 (2.76) ***29.2 (3.71)Body mass index (kg:m2)
5.79 (8.83) nsSmoking (smokes:day) 4.53 (9.57)
CDT Q4:GGT Q1 (S.D.) (n223)Women CDT Q1:GGT Q4 (S.D.) (n194)
5.06 (0.97) ***5.90 (1.09) *Cholesterol (mmol:l)
1.36 (0.33)HDL-cholesterol (mmol:l) 1.62 (0.31) *** ***
0.89 (0.37) ***Triglycerides (mmol:l) ***1.84 (1.41)
28.0 (38.4)Alcohol last week (g) ns22.9 (42.2) ns
2.19 (1.81) ns1.89 (1.99) nsPhysical activity (times:week)
39.1 (10.0) ***Age 53.3 (12.0)
23.1 (2.98) ***30.4 (5.59)Body mass index (kg:m2)
2.08 (5.58)Smoking (smokes:day) 1.80 (4.70) ns
a Pa, P-value adjusted to age and body mass index; ns, nonsignificant. Significance is based on ANOVA.
* PB0.05.
** PB0.01.
*** PB0.001.
men and 42 g per week for women in the highest CDT
quartile, and 138 g per week and 35 g per week in the
highest GGT quartile, respectively. However, this alco-
hol consumption should be considered in the context
that self-reporting of drinking is commonly unreliable,
and the official per capita mean consumption of abso-
lute ethanol in Finland for inhabitants 15 years and
older is 8.4 l per year, corresponding to 162 g per week
[31].
Concerning alcohol induced changes of lipoprotein
metabolism, CDT appears to be associated with an
increased serum HDL cholesterol concentration. In
turn, GGT is known to be related to increased very low
density lipoprotein (VLDL) cholesterol (reflected by
increased triglycerides) [29]. GGT may also reflect in-
creased low density lipoprotein (LDL) cholesterol, since
elevation of VLDL was not large enough to explain the
observed elevation of total cholesterol in the higher
GGT quartiles.
In conclusion, the present results indicate that alco-
hol consumption, as determined by serum CDT concen-
tration, is associated with increased serum HDL
cholesterol and decreased triglycerides. On the other
hand, alcohol consumption associated with liver induc-
tion and elevated GGT may have adverse effects on
lipoprotein metabolism, including hypercholes-
terolemia, and hypertriglyceridemia. CDT and GGT
seem to detect different populations of subjects in re-
gard to lipid metabolism. These observations may lead
to a better understanding of the effects of alcohol
consumption on lipids as well as mechanisms behind
favorable and detrimental effects of alcohol on vascular
diseases.
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